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Abstract 
Facial integrity and self-perception are intimately related to each other. A facial defect 
therefore affects a patient in his physical and psychosocial health as well. Every 
reconstructive method exhibit certain imperfections or burden for the patient, which 
motivates the surgeon’s to strive for improvements. While many imperfections can be 
improved by refinements of the surgical techniques, some aspects might be not solvable by 
surgical principles alone. At that stage, biomedical and engineering methods should be 
considered to complement the surgical treatment for further improvements. 
We developed and explored a variety of biomedical and engineering methods to overcome 
shortcomings of current lip-nose reconstruction techniques. 
The unknown shape of a missing nose was computed from a morphable face model that 
comprise the facial shape information of 200 healthy individuals. It led to a more natural 
shape planning than by hand carving. A biocompatible facial prosthesis was then made out 
of polyamide using computer assisted design and manufacturing. Alternatively to facial 
prosthesis large facial defects can be covered by means of tissue transfer from a distant 
body site performing a microsurgical vascular anastomosis. In this area, the importance to 
develop and use monitoring devices and pharmaceutical drugs for anastomosis patency 
remained unclear. We assessed therefore the current practice for microsurgical head and 
neck tissue transfer in clinics of Germany, Switzerland and Austria. There was a high 
variability with equal success rate, technical monitoring devices and pharmaceutical drugs 
seemed to have a negligible effect on the success rate, while the surgical anastomosis having 
the main effect. To repair small naso-labial defects of inborn cleft lips, the use of the 
adjoining tissue is sufficient. However, since both lip parts contain a labial artery of normal 
thickness they could be as well unified by a microsurgical anastomosis, however its biological 
rational needed exploration. We measured the lip artery blood flow and nose-lip 
microcirculation in cleft lip patients before and after surgical repair and in normal using laser 
Doppler flowmetry and white light tissue spectrometry. We found no circulation deficit in 
cleft patients and therefore no need to strive for a surgical anastomosis. Nonetheless, since 
blood flow is a precondition for growth and development, visible vessels in the surgical field 
should be preserved best possible. We therefore studied the intraoperative vascular 
anatomy for constant vascular findings. A perforating artery of the Musculus transversus 
nasalis was identified at the nasal ala on the cleft side, which could be constrantly preserved 
after it became aware. 
The aim to refine a surgical treatment should not exclusively focus on the surgical technique 
but need also consider the burden of the entire treatment plan. More than 95% of the 
European cleft surgery centers use 2 to 4 surgeries to close the cleft of the lip, alveolus, 
hard, and soft palate –considering that this optimizes growth of the cleft maxilla. But facing 
the burden of repetitive surgeries for patient and family, Dr. Honigmann introduced in Basel 
1991 the cleft repair in one single operation at “one-stage”. We were now able to assess the 
long-term growth effect of this procedure, which showed the same growth results as 
compared to multi-stage procedure. But when compared to normal, 20% to 45% of the cleft 
patients still showed a growth deficit that would require surgery to normalize the dental 
relation and facial profile. The orthognathic surgery rate in cleft patients from the literature 
ranges also widely from about 20% to 45%, whatever surgical technique and treatment plan 
is applied. It is therefore doubtful that by surgical means alone the growth deficit can be 
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avoided. This prompted us to assess the in-vitro and in-vivo osteogenic capacity of stem cells 
from the umbilical cord Wharton’s jelly (WJMSC) under fully defined conditions allowing for 
clinical translation. Due to prenatal ultrasound the cleft lip malformation is frequently known 
before birth, and the umbilical cord could thus serve as an autologous stem cell donor site 
without any harvesting morbidity. Both, Osteogenically differentiated WJMSCs and WJ tissue 
biopsies produced a mineralized extracellular matrix. The expression of genes of osteoblastic 
lineage increased significantly after 3 weeks of osteodifferentiation. Although the WJMSCs 
formed in-vitro a dense collageneous matrix with signs of osteoblastic differentiation, no 
mature bone tissue was found after 8 weeks after subcutaneous implantation in 
immunoincompetent mice. Further in-vivo tests are therefore necessary applying more 
favorable bone forming conditions by using ostegenic predifferentiated cells and 
implantation into a bone defect. 
In sum, biomedical and engineering methods have been applied to solve surgical problems 
or to establish new therapeutic strategies where conventional lip and nose reconstruction 
methods reach their limits. This has been demonstrated at different lip and nose 
reconstructive levels reaching from prosthetics, over microsurgery, to stem cell tissue 
engineering. 
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1. Introduction 
When we look into someone’s face, our gaze fixes on the eyes, lips and nose. These facial 
parts strongly define the facial identity of an individual. Therefore any defect in this facial 
region intimately affects the person’s self-perception. The facial defect thus becomes a 
twofold burden for the patient a physical and psychosocial. This makes it crucial to 
reconstruct the natural form and function of the lip and nose region best possible, and to 
constantly strive for improvements in this field of reconstructive surgery. 
Surgical clinic goes beyond technical aspects. Innovations for surgical treatments must ad 
substantial benefit to the entire process of surgical clinic, otherwise they do not successfully 
translate into clinical routine. The process of surgical clinics can be simplified as interactions 
between surgical technique, patient’s biology and social factors. Ideally an innovation offers 
a well-balanced benefit between these three aspects. Obvious, that a technical 
advancement without biological or social benefit for the patient has minor importance. And 
in turn a specific treatment that appears technically or socially appealing should not 
compromise the biological outcome. 
Surgical improvements rarely appear as radical new techniques. Rather it is an incremental 
process, in which operational steps are reduced, refined, or replaced. That means, the 
improvements commonly either reduces the surgical burden, refine the outcome, or replace 
a current procedure. We herein present surgical and biomedical studies that address specific 
challenges of lip-nose reconstruction, highlighting how they can reduce, refine or replace 
current procedures. Achievements and limitation of each study are outlined in the discussion 
section of the respective study, whereas the thesis discussion outlines how the studies are 
strategically linked striving for new regenerative surgical strategies. 
 
Shape reconstruction of central facial defects  
Facial defects arise secondary to trauma, ablative tumor surgery or inborn malformations. In 
blunt facial trauma, the facial soft tissue breaks open and can usually be completely 
reconstructed by meticulous suturing. In contrast, traumas after wide surgical resection, 
gunshots, burns or animal bites leave defects with a loss of tissue that need to be 
reconstructed by using the patient’s own tissue or a facial prosthesis. 
The most common use of facial prostheses is in the field of tumor surgery. Malignant tumors 
tend to recur. If a few cells are left behind after resection, they can re-grow and lead to a 
new tumor mass within months. Immediate defect coverage with the patient’s own tissue 
may therefore hide tumor re-growth, especially in a complex anatomical area such as the 
nasal cavity. While the reconstruction of lateral facial defects can be guided by the healthy 
counterpart, this is not possible for midline or bilateral facial defects. In such cases the 
reconstruction of a natural-looking facial part and nose relies on the technician’s artistic 
knowledge and taste. 
We describe herein how to compute the three-dimensional shape of a missing facial part 
that is based on the shape characteristics of the remaining face. Furthermore, we have 
clinically tested the direct, computer-aided manufacture of the planned prosthesis. 
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Current standards of microsurgical tissue transfer to the face 
Facial defects that are too large to be closed from the neighboring tissue require 
vascularized free tissue transfer. For this, tissue from a suitable body site is taken including 
its supplying blood vessels and after tissue transfer to the defect site the supplying vessels 
are connected to blood vessels at the defect site. The surgical training and techniques vary 
considerably among different maxillofacial surgical centers to perform such operations as 
well as the used monitoring techniques and pharmacotherapy. This situation prompted us 
first, to assess a survey over routinely applied microsurgical techniques in Swiss, German and 
Austrian maxillofacial centers. Although the survey addressed the topic of microsurgical 
tumor reconstructive surgery, the knowledge about microsurgical technique has an interest 
beyond its classical use for tumor defect reconstruction. Microsurgical techniques are 
optionally to be considered for reconstruction methods including vascularization of large 
tissue engineering constructs and reconstructing the abnormal vascular anatomy in cleft lip. 
 
Introducing the functional vascular anatomy to cleft lip surgery 
The most frequent facial birth defect is the cleft lip and palate malformation, which occurs, 
with varying degrees of severity, in about 1 in 700 newborn babies. This defect may involve 
only the lip or the palate, or both. It may separate the tissues completely or in parts, and 
involve one side of the face or both. However, in all types of cleft malformation, the main 
surgical challenge is to achieve best esthetics and function with a minimal number of 
surgeries and minimal surgical trauma. 
Current surgical techniques for cleft lip repair differ mainly according to the skin incision 
design and the extent of muscle dissection. However, current techniques do not specifically 
address the course of blood vessels and the blood perfusion of the tissue. A striking fact, 
since blood supply is a precondition for growth and development due to it delivering oxygen 
and nutrients to the tissue. As such, microsurgical techniques that respect the vascular 
anatomy during cleft surgery offers an unexplored field to improve cleft lip surgery. 
The vascular anatomy in the cleft lip is altered by the cleft. Normally a lip artery runs from 
both lip sides to the midline where they unify. This normal pattern is interrupted by the cleft. 
However, it is unknown if this leads to an alteration in the tissues blood supply. So far only 
structural anatomical studies exist about the blood vessels in clefts, however, no functional 
conclusions can be deduced from it. There are two principal strategies to influence the blood 
circulation in cleft lip surgery. Either to maximally preserve the main vessels during lip 
surgery or to surgically unify main arteries from both lip sides. 
These options prompted us first to investigate the vascular blood circulation and tissue 
oxygenation before and after cleft repair surgery. This will show, whether current techniques 
lead to a normalization of blood supply or if an attempt to unify the lip arteries should be 
performed. Second, surgical techniques are identified to maximally preserve the 
microvascular anatomy during cleft repair. 
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Combined cleft lip and palate repair to reduce the burden of care 
Disturbance of the upper jaw growth is a frequent problem after cleft lip and palate repair. It 
is commonly considered that repair in two to four separate surgical procedures can minimize 
this problem. However, multiple hospitalization and surgical event is a stressful time for the 
family, which they want to avoid if possible. With the objective to reduce this burden, a one-
stage surgical technique was introduced in Basel 20 years ago, offering obvious social 
advantages. 
We assess herein the long-term growth after one-stage repair of complete cleft lip and 
palatal defects. This clarifies whether the reduction of surgical and psychological burden by 
the one-stage procedure is justified or whether it compromises the biological outcome. 
Umbilical cord stem cells to heal inborn bone defects 
The alveolar bone is the teeth bearing bone of the upper jaw. This region plays a key role in 
growth of the upper jaw and its consecutive teeth relation to the lower jaw. Further, form 
and function of the upper lip is intimately related to the underlying alveolar bone. The cleft 
in the alveolar bone is commonly closed in a separate surgery in preteen age by 
autotransplantation of a pelvic bone graft into the cleft. 
The pelvic bone graft has multiple shortcomings. First, there is a donor site morbidity. 
Second, pelvic bone and craniofacial have a different embryological identity and diverging 
biological behaviors are presumed. The pelvic bone is cartilage derived, whereas craniofacial 
bone forms directly from embryological connective tissue. Third, the bone graft must be 
delayed to preteenage, since earlier grafting leads to growth inhibition and graft resorption. 
Consequently, an autologous graft material, without donor site morbidity, that can be used 
early in life and which complies with craniofacial bone growth would have multiple benefits 
for the patient. 
Umbilical cord stem cells showed in-vitro osteogenic differentiation. Since the clefts 
malformation is commonly diagnosed in the prenatal ultrasound, the umbilical cord could 
potentially serve for a stem cell based strategy to heal the bony cleft. The limitation 
however, is the growth of the cells under a fully defined and regulated protocol leading to 
mature bone formation in vivo. 
We therefore developed a protocol to isolate, expand and cryopreserve Wharton’s jelly 
mesenchymal stromal cells (WJMSCs) under fully defined conditions, devoid of animal-
derived products. The fully defined cultured WJMSCs were included into hydroxyapatite 
granules-fibrin constructs and the bone formation ability was tested in vivo in 
immunoincompetent mice. 
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Abstract 
Mirroring of missing facial parts and rapid prototyping of prosthesis templates have become 
widely used techniques for prosthesis manufacture. However, mirroring is not applicable for 
central facial defects, and the manufacture of a template still requires labour-intensive 
transformation into the final facial prosthesis. We explored innovative techniques for these 
remaining challenges. We used a morphable face model for the reconstruction of non-
mirrorable missing facial parts, and skin-coloured polyamide laser sintering for direct 
prosthesis manufacture. Based on the statistical knowledge gleaned from a data set of 200 
coloured, three-dimensional (3D) scans a missing nose was generated that was statistically 
compatible with the remaining parts of the patient’s face. The planned prosthesis was 
manufactured directly from biocompatible skin-coloured polyamide powder by selective 
laser sintering. The presented prosthesis-planning system produced a normal-looking shape 
reconstruction. The polyamide will need adjustable colouring and the ability to combine it 
with a self-curing resin to fulfil the requirements for realistic permanent use. 
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Introduction 
The engagement and exploration of technology solutions has been identified as a key factor 
for the future of facial prosthetics.1, 2 The computer-aided design and computer-aided 
manufacturing (CAD-CAM) technique is usually used to produce mirror-image templates 
from the non-affected side of the face for realistic remodeling of ear and orbital 
prostheses.3-7 However, in this way CAD-CAM does not realize its full potential to transform 
prosthesis manufacture from an artistic process into a biomedical manufacturing process.2 
First, the problem remains of what should be regarded as normal or ideal, if the defect area 
has no healthy mirror image. Second, the labour intensive transfer of the CAD-CAM template 
into the final prosthesis remains. We therefore explored innovative solutions to these two 
challenges. 
In the present study we used a morphable model as a planning innovation for facial 
prosthetics, which allows patient-specific shape reconstruction in cases where the mirroring 
technique is not applicable or undesirable. We also explored automatically defining the 
margin using distance mapping and the use of a skin-coloured medical-grade polyamide 
laser-sintering process as a manufacturing innovation for facial prosthetics. 
 
 
Materials and Methods 
The study was approved and found to meet the ethical standards of the declaration of 
Helsinki. The patient in this study was referred to us with recurrence of a sclerosing basal cell 
carcinoma of the nose. He underwent total rhinectomy, including resection of the anterior 
nasal floor, premaxilla and anterior wall of the right maxillary sinus. 
To model the missing facial subunit, we developed a morphable model of human faces.8 The 
morphable model was computed from a data set of 200 three-dimensional (3D) scans of 
male and female Caucasian faces. Dense point-to-point correspondences to a reference face 
were computed for the individual faces. This resulted in a single vector space of faces. 
Hence, the morphable model can generate continuous transitions between the faces and 
form linear combinations thereof. 
The patient’s face was scanned three-dimensionally (ABW, Frickenhausen, Germany). The 
face scan was automatically matched with the morphable face model using a non-rigid 
registration algorithm.9 This produced a complete face that was congruent with the healthy 
parts of the patient’s face. 
The prosthesis margins were defined using an automated distance-mapping process. The 
facial defect borders protruded inward, while the generated nose shape protruded outward. 
The points of minimal distance form the margin line. The final prosthesis plan was 
superimposed onto a computed tomography (CT) scan of the patient. This allowed to check 
the bone quality at the planned implant positions and the leeway for precision attachments 
at the planned implant positions . 
The planned prosthesis was directly manufactured on an EOSINT P machine (EOS, Munich, 
Germany) using CO2-laser sintering of PA2200 polyamide powder, with a layer thickness of 
0.1–0.15 mm. The prosthesis margins were adapted to the patient’s facial movements by 
milling off areas of interference. Four magnetic precision attachments were polymerized into 
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recessed boreholes at the implant sites. The surface of the prosthesis was finalized using 
watercolours and a layer of varnish. 
The prosthesis was scanned by a laser (VI-910, Konica Minolta, Munich, Germany) before 
and after the margin adaptation. Both scans were superimposed on the unchanged nasal 
shape and a false-colour area map was used to analyse the extent of necessary margin 
reduction. 
 
 
Results 
The algorithm of the morphable face model generated a nose reconstruction with a natural-
looking shape (Fig. 1), which fitted harmoniously to the patient’s face. 
 
 
 
Fig. 1. The morphable model is a statistical model, computed from 200 
three-dimensional (3D) face scans of young adults, which can form 
continuous transitions between the individual faces. The healthy part of 
the patient’s 3D face scan is expressed in terms of this morphable face 
model, which consecutively provides a reconstruction for the missing facial 
part. The generated reconstruction is unique, statistically consistent with 
the patient’s face and independent of the artistic skills of a prosthetist. 
 
The polyamide laser sintering resulted in a nearly homogeneous surface which was 
polishable using standard millers and polishers. The intrinsic stain of the PA2200 polyamide 
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was darker than the patient’s skin colour, which could not be corrected by a coat of paint 
(Fig. 2). 
 
  
Fig. 2. Laser sintered prosthesis direct from 
the plan made of biocompatible, skin-
coloured, PA2200 polyamide powder. The 
prosthesis margin, as defined by distance 
mapping, resulted in complete defect 
coverage with circumferential skin contact 
but it needs fine adjustment with a self-curing 
material to become inconspicuous. It was not 
possible to match the extrinsic staining to the 
patient’s skin hue due to the intrinsic staining 
of the PA2200 polyamide, which was too dark 
and invariant. Published with the patient’s 
consent. 
Fig. 3. Polymethylmethacrylate duplication 
of the laser sintered prosthesis with 
conventionally adapted margins. The 
morphable-model-based nasal 
reconstruction generated a natural-looking 
shape reconstruction of the nose that fits 
harmoniously to the patient’s face. 
Published with the patient’s consent. 
 
 
The automatic margin definition achieved by distance mapping led to complete coverage of 
the defect area. Since polyamide cannot be added with self-curing resin the margin line was 
planned with a circumferential safety border of 2 mm. Adaptation of the prosthesis margins 
on the patient resulted in a maximal margin reduction of 3.9 mm. This was necessary at the 
nasal bridge, below the right lower eyelid and at the nostrils.  
The transition between the margins and the skin could not be leveled out completely, since 
polyamide is not combinable with self-curing resin. Because of the shortcomings, a duplicate 
polymethylmethacrylate prosthesis was constructed, in which colour and margin adaptation 
was optimized while keeping the nasal shape unchanged (Fig. 3). The duplicate prosthesis 
served for permanent use. 
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Discussion 
 
Morphable modeling 
The face is the visible part of a person’s unique identity. In central facial defects and after 
total rhinectomy there is no contralateral side available to act as a shape reference for 
reconstruction and the method of choice is often a prosthetic reconstruction  10,11 In these 
cases, the shape of the prosthesis lies in the hands of the maxillofacial prosthetist, whose 
artistic skill gives the patient back his or her facial identity. Morphable modeling can provide 
complete 3D shape information of a missing facial part based on the remaining facial 
characteristics of the patient. In the present case the shape of the generated nose was 
comparable to that observed in photographs of the patient’s original state (Fig. 4). 
 
 
Fig. 4. The patient’s original nasal shape, as seen on a old 
photograph. The automatically generated nose (Fig. 3), was 
slightly underprominent when compared to the original shape, 
which can be attributed to the young age of the reference faces 
upon which the morphable model was based. Published with 
the patient’s consent. 
Overall, the generated nose was slightly underprominent. One reason for this is that the 
morphable model is based on 200 facial scans of young adults, and the nose is known to 
become more prominent throughout life. 
The proposed shape of the morphable model can be adjusted manually with respect to three 
facial attributes: male–female, bony–fleshy and facial distinctiveness (the degree to which 
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the face differs from the average face).8 This allow fine adjustments according to the 
patient’s facial characteristics and wishes. Age- and ethnicity-related facial attributes would 
also be helpful to complete the medical applicability of the morphable model. 
Two-dimensional (2D) photographs of the patient’s original state are traditionally used to 
guide the technician when shaping a wax model. Our morphable face model allows a 3D 
visualization to be produced from scanned 2D photographs of the patient’s original state.12 
Currently such a visualization does not contain sufficient 3D shape information for 
transformation into a rapid-prototype model. However, it can be used for the fine 
adjustment of the proposed shape in the morphable model. 
The combined data set of CT scan and planned prosthesis allows a simultaneous visualization 
of bone conditions, prosthesis thickness and soft-tissue thicknesses. This helps to define the 
optimal implant position and type of implant. If necessary, the marked implant position and 
axis can be used for intraoperative navigational support. 
Simulation systems for craniofacial surgery have become an important tool for the clinician. 
The trend towards web-based applications, as seen in home computing, might also 
increasingly affect craniomaxillofacial applications.13 The algorithm of the morphable model 
has been published, and open-source implementation is therefore technically feasible. 
 
Laser sintering 
A crucial step in the manufacture of a prosthesis is the correct colour and an inconspicuous 
transition to the skin. The application of CAD-CAM techniques allows both of these 
requirements to be achieved if manual adjustments are made on a wax template and 
silicone is used.14 This might improve the results achieved by the maxillofacial prosthetist, 
but it does not substantially shorten the manufacturing process of a manual prosthesis. 
A rapidly manufacturable material for direct prosthetic use would shorten the 
manufacturing process, and hence it would open new opportunities for facial prosthetics by 
reducing the time and effort of manual manufacturing, evolving facial prosthetics from an 
art into a field of biomedical engineering, attracting industry partners, and making facial 
prosthetics more widely available including in new applications such as temporary 
prostheses or prosthesis-dressing combinations.  
Polyamide is availabe as a rapidly manufacturable, biocompatible and skin coloured 
material. PA2200 polyamide is a fine powder based on a polymer of lauryllactam (C12H23NO) 
and is tested for polonged skin contact according to International Organization for 
Standardization ISO 10993-1. After laser sintering the polyamide is a physically and 
chemically durable material with low density (0.9–0.95 g/cm3), which render the material 
suitable for implant and glued fixation. 
The direct manufacture of realistic facial prostheses requires two improvements to PA2200 
polyamide: (1) the intrinsic staining must be adjustable to make it better match the skin 
colour and (2) a self-curing material must be combinable with PA2200 to level out the 
transition between the prosthesis and skin. The prosthesis margin, as defined by distance 
mapping, resulted in complete defect coverage with circumferential skin contact, but it 
needs fine adjustment with a self-curing material to become inconspicuous. 
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Material scientists could solve these shortcomings. Further, the development of a soft, 
rapidly manufacturable material is necessary, since a soft material usually fits better at the 
margins and conforms better with facial movements. 
 
 
Conclusions 
The morphable face model can reconstruct realistic facial parts in cases where mirroring is 
not applicable. The technique reduces the dependence on the artistic skills of a technician. 
The direct manufacture of a prosthesis from biocompatible skin-coloured PA2200 polyamide 
by selective laser sintering currently only fulfils the requirements for temporary use. 
Adjustable colouring and compatibility with a self-curing resin is necessary to reach the 
requirements for permanent use. 
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Abstract 
Refinement in microvascular reconstructive techniques over the last 30 years has enabled an 
increasing number of patients to be rehabilitated for both functional and aesthetic reasons. 
The purpose of this study was to evaluate different microsurgical practice, including 
perioperative management, in Germany, Austria, and Switzerland. 
The DÖSAK collaborative group for Microsurgical Reconstruction developed a detailed 
questionnaire which was circulated to units in the three countries. The current practice of 
the departments was evaluated. 
Thirty-eight questionnaires were completed resulting in a 47.5% response rate. A 
considerable variation in the number of microsurgical reconstructions per year was noted. In 
relation to the timing of bony reconstruction, 10 hospitals did reconstructions primarily 
(26.3%), 19 secondarily (50%) and 9 (23.7%) hospitals used both concepts. In the 
postoperative course, 15.8% of hospitals use inhibitors of platelet aggregation, most 
hospitals use low molecular heparin (52.6%) or other heparin products (44.7%). 
This survey shows variation in the performance, management, and care of microsurgical 
reconstructions of patients. This is due in part to the microvascular surgeons available in the 
unit but it is also due to different types of hospitals where various types of care can be 
performed in these patients needing special perioperative care 
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Introduction 
Reconstructive surgery that allows free transfer of soft tissue and bone from all over the 
body following resection for head and cancer or after trauma is considered when there is a 
functional or aesthetic loss of structures. Depending on the site, size and complexity of the 
defect, the reconstruction may involve free tissue transfer of soft tissue, bone or a 
composite of both. The operation is complex and time-consuming and surgeons have to 
learn both the techniques of raising flaps of different types and microsurgery. In addition to 
the surgical requirements, other problems include the co-morbidities often seen in these 
patients, particularly heavy smoking, alcohol abuse and age-related conditions. These can 
affect intraoperative and postoperative management. High dependency care is usually 
required postoperatively and varying pharmacotherapeutic and intensive care regimens can 
influence flap success or failure. Although the mortality of this type of surgery is low, the 
physical and psychological impact on the patient is significant. These operations involve a 
large investment of resources, in both time and monetary terms. Despite these issues, there 
is limited clinical outcome data published relating to the current practice of reconstructive 
surgery and microsurgical practice. Where these exist it is usually based on departmental 
and personal practices (Kruse et al., 2010; Marsh et al., 2009; Spiegel and Polat, 2007). The 
purpose of this study was to evaluate current practice in reconstructive surgery and the 
different strategies including the perioperative management of microvascular cases in 
Germany, Austria, and Switzerland. 
 
 
Material and Methods 
Using the German, Austrian and Swiss Association of Oral and Maxillofacial Surgeons 
database of oral and maxillofacial hospital units, 82 separate units were identified. A 
questionnaire was developed by the DÖSAK collaborative group for Microsurgical 
Reconstruction to evaluate the following information: number of surgeons in the 
department, number of microsurgeons performing anastomoses regularly, number of 
patients receiving free microsurgical flaps per year, type of free flaps, and type of 
osteosynthesis for insertion of flaps containing bone. Information about the surgeons’ 
opinion regarding the influence of perioperative treatment was assessed on a scale from 1 to 
7 (1 = not important, 7 = most important). A second part of the questionnaire focused on the 
different perioperative stages of managing microsurgical patients as classified by Chen et al. 
(2006). The survey was performed by sending the questionnaire to the heads of each unit via 
Email and via mail in June 2009. Evaluation of questionnaires was performed after 6 months. 
 
Data analysis 
Descriptive statistics for quantitative variables are given as the mean standard deviation. If 
appropriate, medians and ranges were also computed. Statistical analysis was performed 
using JMP 7.0.1 (SAS Institute Inc., SAS Campus Drive, Cary, NC 27513, USA) Microsoft Office 
Excel (Microsoft Excel for Windows, release 2007, Microsoft Corporation, Redmond, WA, 
USA). 
Results 
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In total, 38 questionnaires were completed adequately and 2 returned undelivered (47.5% 
response rate). Of these departments, 21 were University hospitals (55.3%), and 17 General 
hospitals (44.7%). 
 
General microsurgical performance 
The size of the department in the contributing hospitals varied from hospitals with 3 
surgeons to one with 22, a mean of 12.7 ± 5.6 surgeons (median 12, range 3e22 surgeons). 
The number of surgeons regularly performing microsurgical procedures was 3.4 ± 1.5, range 
from 1 to 7 surgeons (median 4, range 1e7). Eight hospitals treat less than 50 patients with 
oral squamous cell carcinoma per year (21%), 20 hospitals see 50e100 patients (52.6%), 10 
more than 100 patients per year (26.3%). Numbers are clearly lower for cases undergoing 
microvascular reconstruction as not every cancer case requires this form of treatment (13 
(34.3%) versus 15 (39.5%) versus 10 (26.3%)). There was a considerable variation in the 
number of microsurgically performed cases per year (Table 1). The microvascular free flaps 
used for reconstruction of defects are shown in Table 2. In relation to timing of bony 
reconstruction, 10 hospitals did reconstructions primarily (26.3%), 19 secondarily (50%) and 
9 (23.7%) hospitals used both approaches. Frozen sections are performed in the vast 
majority of participating hospitals to optimize tumour resection intraoperatively (86.8%). For 
reconstruction of osseous defects, both mini-plates (42.1%) and reconstruction plates 
(23.7%) are used. One-third of hospitals (31.6%) use both systems. 
 
Table 1. Number of cases by units per year (n= 38). 
 
 
Table 2. Different flaps performed by units per year (n = 1300). 
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Preoperative management 
Twenty-eight hospitals (73.7%) perform special preoperative management before a 
microvascular procedure in cases where bone is necessary for reconstruction. These units 
perform angiography for a fibular bone graft for vessel evaluation and possible stenoses of 
the branches or anatomical variations (Hölzle et al., 2010b). The Allen’s test is performed if 
the radial forearm flap is used (Williams and Schenken, 1987). 
 
Intraoperative management 
Perioperative anticoagulation is used by 28 hospitals and is mostly heparin, followed by 
HAES (Hydroxyethylstärke) and acetyl-salicylic acid (ASS) (Fig. 1). Application protocols vary, 
as it is started both before, at time of and after ischemia. Most units apply pharmacological 
anticoagulation before (15–30 min) or immediately after completion of the anastamosis and 
before re-establishing of blood flow (Table 3). 
 
 
Fig. 1. Anticoagulation used in different units used for perioperative or postoperative treatment. 
 
Table 3. Time point of perioperative anticoagulation performed in different units. Note how many 
units do not perform “anticoagulation”. 
 
 
44.7% of surgeons performed only an end-to-end technique in arteries and 10.5% in venous 
vessels. 34.2% of surgeons use end-toside technique in veins. Vessel grafts were never or 
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rarely used by 15.8% of hospitals and only in 1 hospital (2.6%) were they used regularly. 
Most hospitals flush recipient vessels (71.7%) intraoperatively, using heparin or saline. 
Intraoperative infusion therapy for vessel resistance reasons after anastamosis was applied 
in the minority of cases (26.3%), using HAES. Steroids are given in one third of cases (33.3%). 
 
Postoperative management 
15.8% of hospitals use inhibitors of platelet aggregation postoperatively; most hospitals use 
low molecular heparin (52.6%) or other heparin products (44.7%). HAES was used by 26.3% 
of hospitals for prevention of systemic venous thromboembolism and specifically 
prophylactically for the microvascular anastamosis (Mardel et al., 1996). When asked about 
the impact of supportive measures, substances were rated as presented in Fig. 1. The ratings 
regarding postoperative monitoring, influence of medication, and experience in 
microsurgical technique are presented in Fig. 2. 
 
 
Fig. 2. Ratings regarding the importance of postoperative monitoring (mean 4.3), experience in 
microsurgery (mean 5.8), and anticoagulative or rheologic medication (mean 2.8) asked on a scale 
from 1 to 7 (1 = not important, 7 = most important). 
 
 
Discussion 
This study revealed that in most of the units responding to the questionnaire reconstructive 
microsurgical practice is performed frequently in German, Austrian and Swiss Departments 
of Oral and Maxillofacial Surgery. Although we had access to all the maxillofacial units in all 
three countries we expected a lower response rate from those not performing free flaps. 
This might be an explanation for our 48% response rate overall. Of the replies received, 95% 
did perform microsurgical free flap reconstruction. We therefore believe that our survey is 
likely to be representative of the current practice of the participating units. This type of 
surgery is performed in many units in Germany, Austria, and Switzerland, both in General 
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and University hospitals, and there was a wide variability in the number of cases performed 
by each unit per year. Only 2 units perform more than 100 cases, and 18 units perform more 
than 50 patients per year, representing t half of all units performing microsurgical and 
reconstructive surgery who had responded to the questionnaire. Only 9 units performed less 
than 20 cases per year. 
In one of the largest surveys performed (Salemark, 1991), microsurgical procedures 
performed in the year 1989 in Departments of Plastic and Reconstructive Surgery worldwide 
were evaluated. In 83 units about 6500 operations were performed, but all body sites and 
reimplantation surgery were included. Whitaker et al. (2007) reported in a monthly-based 
analysis in Britain, that 75% of participating units had been performing 2e5 cases per month 
(24e60 per year) which is in the same range as our results, although the numbers presented 
in this survey are overlapping in this point (Table 1). Similarly in our survey only a few 
centres had performed more than 100 cases per year. These results show that microsurgical 
operations are regularly performed in Britain. Although these data are not comparable to 
each other, they show that the frequency of microsurgical reconstructive procedures has 
increased over the last decades. This is also related to the development and refinements of 
postoperative management performed regularly in major oncologic and reconstructive 
surgery as reported in the literature (Bradley, 2007; Bui et al., 2007; Chen et al., 2006; Marsh 
et al., 2009). 
Postoperative care and monitoring were felt to be important by all the units despite wide 
variations in practice and the absence of any standard monitoring devices (Fig. 2). This 
suggests that the success rate does not depend on the postoperative medication regimen, 
supported by anticoagulation and vessel resistance treatment. Although several studies have 
been described in the literature, there is still no consensus regarding the optimal treatment 
regimen for anticoagulation in microvascular free flap surgery (Ashjian et al., 2007; Chien et 
al., 2005; Davies, 1982). Interestingly, in the literature different monitoring modalities, 
varying from clinical observation to technical devices for the detection of flap compromise, 
were not associated with a higher success rate or a lower complication rate (Spiegel and 
Polat, 2007). This also reflects the importance of experience in microsurgical procedures and 
individual flap management as rated by the different departments (Hölzle et al., 2010a; 
Kruse et al., 2010; Salemark, 1991; Smit et al., 2007). 
 
 
Conclusions 
This survey shows variation in the management and care of patients who have undergone 
microvascular reconstruction. This is due in part to the availability of microvascular surgeons 
in the different units, but it is also due to different types of hospitals where various levels of 
care can be provided for these patients needing special perioperative management. The lack 
of robust data is likely to continue with the presence of multiple small units with different 
practice performed in oral and maxillofacial surgery. Consolidation of data into a national or 
an international database would seem logical to inform decision-making and also to allow 
meaningful analysis of unit performance. This database would be also beneficial for 
evaluating different applications of microsurgical and reconstructive practice, both from the 
oncological and surgical points of view. 
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Abstract 
Cleft lip repair aims to normalize the disturbed anatomy and function. We determined 
whether normalization of blood circulation is achieved. 
We measured the microcirculatory flow, oxygen saturation, and hemoglobin level in the lip 
and nose of controls (n=22), and in patients with unilateral and bilateral cleft lip and palate 
(UCLP and BCLP, respectively). We measured these parameters before lip repair (n=29 and 
11, respectively), at the end of lip repair (n=27 and 10, respectively) and in the late post-
operative period (n=33 and 20, respectively). The arterial flow velocity was measured in 
UCLP groups at the same time points (n=13, 11 and 12, respectively). Statistical differences 
were determined using analysis of variance. 
Before surgery, the arterial flow velocities and microcirculation values were similar on each 
side of the face and among the groups. The microcirculatory flow was significantly higher in 
the prolabium of BCLP patients than in the philtrum of controls. All circulation values in UCLP 
and BCLP patients in the late post-operative period were within the range of controls and of 
those before surgery. Intraoperatively, we consistently found a perforating artery on the 
superficial side of the transverse nasalis muscle. 
There appears to be no intrinsic circulatory deficit in UCLP and BCLP patients. The increased 
flow in the prolabium indicates a strong hemodynamic need in this territory, compelling its 
vascular preservation. Whether the surgical preservation of the nasalis perforator artery is of 
long-term benefit should be addressed in future studies. 
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Introduction 
Cleft lip repair techniques differ mainly in the design of the skin incisions, how the muscle 
portions are reconstructed, and how the nasal framework is repositioned.1 The vascular 
anatomy has remained largely unaddressed in current surgical techniques and the reasons 
for this have yet to be explored. 
Normal blood supply is a precondition of development and growth. Thus, it would be of 
clinical interest to determine whether cleft anatomy leads to a change in the blood supply 
before or after surgery. 
Current techniques for cleft-lip repair exclude surgical anastomosis of the lip artery. 
However, this clinical approach is not based on blood circulation data and so the current 
standard must be challenged. Vascular damage in cleft surgery interrupts the existent 
hemodynamics and necessitates further trauma to stop the bleeding, after which the blood 
circulation may take several months to recover.2 Gentle surgical soft-tissue handling with 
blood vessel preservation is perhaps one of the decisive factors, why long-term outcome is 
better if the cleft surgery is performed by experienced surgeons operating with “soft 
hands.”3,4 
Cadaver cleft lip studies provide timeless information on the vascular network, but they lack 
in-vivo functional information.5-9 To improve our understanding of the blood circulation in 
cleft lip, we assessed both the arterial vascular flow and the microcirculation before, at the 
end and late after cleft lip repair, as well as in a healthy control group. The results are 
discussed in relation to the vascular anatomy encountered during cleft lip surgery and in 
relation to the vascular anatomy of normal cadaver dissections. 
 
 
Material and Methods 
 
Patients and surgery 
Ethical committees at the institutions of two of the authors (A.A.M. and S.G.R.) approved the 
study protocol. We included patients with unilateral or bilateral complete cleft lip and palate 
(UCLP and BCLP, respectively). Those in the healthy control group had undergone various 
surgical procedures, while having a healthy nose-lip anatomy. During the measurements the 
patients were kept in a supine position and under general anesthesia. All patients were 
operated on by the same surgeon (R.R.R.) using a previously published surgical technique.10 
Before the skin incision, 1 ml of lidocaine (1%) with epinephrine (1:100,000) was injected 
submucosally and intramuscularly along the incision markings. Bipolar cautery was used to 
stop bleeding that was not stopped by compression (Force FX coagulation system, Valleylab, 
Colorado, USA). 
We measured the microcirculation in the following groups: 
Controls (n=22). 
UCLP patients before lip repair (n=29). 
UCLP patients at the end of lip repair (n=27). 
UCLP patients in the late post-operative period (n=33). 
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BCLP patients before lip repair (n=11). 
BCLP patients at the end of lip repair (n=10). 
BCLP patients in the late post-operative period (n=20). 
We measured the arterial vascular flow in the following groups: 
UCLP patients before lip repair (n=13). 
UCLP patients at the end of lip repair (n=11). 
UCLP patients in the late post-operative period (n=12). 
We defined “late post-operative” as more than 6 months after lip repair. All patients 
measured at the end of lip repair had also been measured before surgery. 
 
Microcirculation flow, oxygenation, and hemoglobin 
Peripheral tissue perfusion was assessed using the O2C-1212 measuring system (LEA 
Medizintechnik, Giessen, Germany).11 This system combines white-light tissue spectrometry 
and laser Doppler flowmetry and makes the following measurements simultaneously: 
(1)  The microcirculatory flow in vessels less than 100 µm in diameter, expressed in 
arbitrary units. 
(2)  The post-capillary oxygenated hemoglobin, expressed as a percentage of the total 
hemoglobin. 
(3)  The relative hemoglobin level in vessels less than 100 µm in diameter, expressed in 
arbitrary units. 
We used an LSx-8c probe to make measurements on the columella; for all other points we 
used an LF-2 probe (tip diameter 4 mm and 12 mm, respectively). The approximate 
detection depths of the probes were 0.88 mm (LSx-8c) and 1.41 mm (LF-2). To avoid 
pressure-induced flow artifacts, we fixed the probes to the skin with double-sided adhesive 
tape (LTDT-001). 
To allow for comparisons between the groups, we set the measuring points on the 
keratinized skin at corresponding anatomical landmarks (Fig. 1, circles): lateral lip, cupid, 
philtrum or prolabium, columella and ala. In UCLP patients we classified the symmetrical 
points as cleft- (C) or noncleft (NC)-sided, whereas in BCLP patients and controls we 
classified them as right- and left-sided. 
 
Arterial flow velocity 
The arterial blood flow velocity was assessed using a continuous-wave Doppler device (EZ-
Dop, Compumedics, Singen, Germany) employing an 8-MHz probe with a tip diameter of 
4 mm (HD.CW0800.06, MTB Medizintechnik Basler, Regensdorf, Switzerland). The probe 
angulation was chosen to maximize the signal, and the mean and maximum velocity (in 
cm/s) values were recorded. 
We measured the blood flow velocity in the superior labial artery at the height of the labial 
commissure, cupid point and labial tubercle. At the alar base and columella we measured 
the blood flow velocity in the detected artery, regardless of the origin of its arterial main 
supply (Fig. 1, rectangles). 
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Fig. 1. Sites where the blood circulation was measured. At the points marked by open circles, we 
measured the microcirculatory flow, oxygen saturation and hemoglobin levels with an optical 
probe through the keratinized skin. At the points marked by filled rectangles, we measured the 
flow velocity in the underlying artery with an 8-MHz sound Doppler device. Corresponding sites 
were measured before and after surgery in unilateral and bilateral cleft lips, and in healthy 
controls. 
 
Statistics 
We performed a one-way analysis of variance (ANOVA) of data from identical or symmetrical 
measuring points. We used Tukey’s multiple-comparison test to detect differences between 
groups, and between cleft and noncleft sides. 
 
Anatomical dissections 
The facial arterial network was dissected in 12 adult, formalin-fixed cadavers with the aid of 
a surgical microscope and microsurgical instruments (S&T, Neuhausen, Switzerland). 
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Results 
 
Arterial blood flow velocity 
No significant differences in vascular blood flow velocities were found at corresponding 
measuring points between the cleft and noncleft side, and between the different groups 
(p=0.05, ANOVA with Tukey’s post-hoc comparisons) (Table 1). 
 
Microcirculatory flow 
The microcirculatory flow was significantly higher in the prolabium of BCLP patients before 
lip repair than in the philtrum of UCLP patients and controls. The microcirculatory flow was 
significantly lower at the end of lip repair than before lip repair at two points: in UCLP 
patients at the noncleft side ala, and in BCLP patients at the left ala. In addition, the 
microcirculatory flows at corresponding points was similar on the cleft and noncleft sides in 
UCLP patients, BCLP patients and controls, and before, after and later after lip repair 
(p=0.05, ANOVA with Tukey’s post-hoc comparisons) (Table 2). 
 
Post-capillary hemoglobin oxygenation 
The hemoglobin oxygen saturation in the cleft-side lateral lip in UCLP patients was 
significantly lower at the end of lip repair than before lip repair. In addition, the 
microcirculatory oxygen saturation was similar on the cleft and noncleft sides in UCLP 
patients, BCLP patients and controls, and before, after and later after lip repair (p=0.05, 
ANOVA with Tukey’s post-hoc comparisons) (Table 3). 
 
Microcirculatory hemoglobin level 
The relative hemoglobin level in the columella of UCLP patients was significantly lower 
before lip repair in UCLP patients that in BCLP patients and controls, while it was significantly 
higher in UCLP patients at the end of lip repair than before lip repair or in the late post-
operative period. Furthermore, the relative hemoglobin level in the late post-operative 
period was similar on the cleft and noncleft sides in UCLP patients, BCLP patients and 
controls, and compared to before lip repair (p=0.05, ANOVA with Tukey’s post-hoc 
comparisons) (Table 4). 
 
Vascular anatomy in cadaver dissections 
The following findings were encountered consistently in the dissections. The thickness of the 
superior labial artery was asymmetric in most cases (Fig. 2, left and lower right). The 
dominant side connected to a branch to the labial tubercle and to at least two philtral 
branches (Fig. 2, left and lower centre): a thick branch deep to the muscle and a thinner one 
superficial to it. The deep philtral branch ran around the lip muscle in front of the anterior 
nasal spine and connected to the columellar branch (Fig. 2, left and lower centre), while the 
superficial philtral branch ramified to the caudal nasal septum (Fig. 2, upper centre). The 
superior and inferior alar arteries connected either caudally to the superior labial artery 
(Fig. 2, left) or laterally to the facial artery (Fig. 2, lower right). 
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Fig. 2. Characteristics of the normal vascular anatomy. The superior labial artery (SLA) is dominant 
on one side (). The superficial (- - >) and deep (▲  ) philtral artery, and the labial tubercle branch 
(#) is mainly supplied by the dominant side. The deep philtral artery runs posteriorly to the labial 
muscle (*) and connects to the columellar artery (Δ); whereas the superficial philtral artery ramifies 
(Λ) to the caudal nasal septum. The arterial trunk of the ala and inferior alar artery (IAA) connects 
either caudally to the superior labial artery (Left, cadaver’s both sides) or laterally to the facial 
artery (FA) (Upper right, cadaver’s right side). Scale increments indicate millimeters. FV, facial vein. 
 
Vascular anatomy in cleft lip repair 
On the noncleft side we frequently encountered an artery of 1–2 mm in diameter in the 
submucosa of the lip band, running along the posterior side of the lip muscle (Fig. 3). During 
the subperiostal approach to the caudal septal part, this artery was laterally shifted and 
preserved. On the cleft side we encountered a submucosal lip artery more rarely. 
 
 
Fig. 3. Superior labial artery on the noncleft side. (Left) Frequently, the artery proceeds to the labial 
tubercle and can be localized before surgery by its strong Doppler signal. (Centre) During surgery, 
the artery (▲  ) is encountered in the submucosa of the lip band and can be frequently preserved. 
(Right) The caudal septum (*) is approached from the cleft side and does not interfere with the 
artery. 
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On the cleft side, we consistently encountered an artery of 1–2 mm diameter in the 
subcutaneous plane of the hairy nostril skin – the artery perforated out of the inferior head 
of the transverse nasalis muscle (Fig. 4). The bleeding that occurred when the artery was 
accidentally cut always required coagulation. This artery was equally present in UCLP and 
BCLP patients. 
 
Fig. 4. The perforating artery of the transverse nasalis muscle on the cleft side. (Upper left and 
right) In the subcutaneous plane of the hairy nostril skin, a 1- to 2-mm-thick artery is consistently 
found during dissection of the transverse nasalis muscle, which is held in the forceps. (Upper right 
and lower right) The localization and course of this artery is constant, which makes its surgical 
preservation easier. 
 
In the prolabium of BCLP patients we regularly encountered two arteries (Fig. 5) running on 
the right and left sides of the prolabium, being most superficial at the midway point 
between the columella–prolabial junction and the planned cupid points. 
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Fig. 5. The prolabium arteries. (Left) In the middle of the prolabium, between the columella base 
and the planned cupid points, a pair of prolabium arteries (- - >) is frequently observed running 
subcutaneously. (Right) While dissecting the prolabium from distal to proximal under constant 
tension, these arteries can be identified and preserved independently of the skin incision design. 
 
 
Discussion 
 
Circulation before lip repair 
Before surgery, the arterial flow velocities and microcirculation values were symmetric on 
the cleft and noncleft sides, as well as among cleft groups and controls. Despite the aberrant 
cleft vascular anatomy, a symmetric and normal blood supply was found. Cleft repair should 
aim to preserve this function. 
Anatomical studies have demonstrated that the superior labial artery is thicker on the cleft 
side than on the noncleft side and a fibrosis of the unoperated cleft muscles has been 
presumed.5,12 However, no corresponding circulatory discrepancies have been found, which 
underlies the need to complement morphological descriptions with appropriate functional 
measurements. 
While the blood supply on the cleft and noncleft sides did not differ from controls, there was 
a difference in the midline blood supply. The prolabium of BCLP patients had a significantly 
increased microcirculatory flow and the columella of UCLP patients had a significantly 
decreased hemoglobin level. 
In a circulatory steady state the hemoglobin level reflects the microvascular density in the 
tissue. The columella in UCLP patients lacks the connection of an inferior alar artery on the 
cleft side, and thus its hemodynamic force to the columella.13,14 Since the hemodynamic 
force is a key stimulus for the development and maturation of the vascular bed, this might 
partially explain the decreased relative hemoglobin level in the UCLP columella. 
In the prolabium of BCLP patients we attribute the increased microcirculation flow to a 
strong hemodynamic need in this territory. The nutritive needs of the premaxilla might be 
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not fully met by the posterior septal artery, thus requiring a complementary supply from the 
prolabium circulation.8 
 
Circulation at the end of lip repair 
The microcirculation flow in the prolabium of BCLP patients remained higher than in controls 
and UCLP patients, both directly at the end of lip repair and in the late post-operative 
period. We attribute this to the intraoperative vessel preservation in the prolabium (Fig. 5). 
The surgical repair in BCLP did not reduce the high microcirculation flow in the prolabium, 
and thus we assume that the microcirculatory requirements were maintained. 
A venous stasis in the microcirculation can be detected by an increase in hemoglobin level 
together with a decrease in flow. We encountered this at the end of lip repair in the 
columella of UCLP patients. The venous drainage through the columella runs in normal 
anatomy to the philtral plexus and to the septal mucosa plexus.15,16 Thus, release of the 
caudal septum and the medial rotational incision might have interfered temporarily with the 
venous drainage – even though the medial rotation incision did not cross the midline. A 
sharp downturned back-cut was performed as necessary in the midline to allow for rotation 
(Fig. 4, upper left). 
The blood circulation at the end of lip repair is influenced by multiple factors, including 
surgically induced vasodilatation, vascular coagulation, change in tissue tension, and 
systemic hemodynamic conditions. Thus, assumptions about cause-and-effect relationships 
must be made with caution. However, the cumulative effect of these factors appears to have 
led to an arterial blood flow velocity and microvascular flow in the lip and philtrum at the 
end of surgery that did not differ from the corresponding preoperative data. It is thus 
understandable that the evolution from staged to synchronous bilateral cleft lip repair 
proceeded without healing problems. 
 
Circulation in the late post-operative period and in normal controls 
In the late post-operative period, the arterial blood flow velocity and microcirculation in 
UCLP and BCLP patients was the same as in controls and the same as before surgery. We 
conclude that cleft lip repair without a surgical anastomosis of the lip artery allowed for 
normal circulatory development. This is consistent with the blood supply observed in normal 
faces, wherein the circulation is balanced on each side of the face independently and does 
not rely on a superior labial artery anastomosis.17-20 The microcirculation measurement 
depth of 1.41 mm corresponds to the deep reticular network of the skin. This network is fed 
by collaterals of the superior labial artery and is therefore related to the circulation in the lip 
muscle.21,22 
Hemodynamic forces are key elements for the remodeling of the vascular network after 
acute arterial occlusion. In arteriogenesis, shear stress induces the recruitment of arteriolar 
collaterals, which in turn differentiate into new arteries.23,24 The circulation was completely 
restored after carotid ligation in growing animals, but there was a reduction in facial muscle 
weight.25 Thus, the recovery of blood circulation observed in the present study may not 
represent the recovery of growth potential. 
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Intraoperative arteries 
The cleft interrupts the normal course of the superior labial artery. Published schematic 
illustrations show that the superior labial artery on the cleft side runs to the alar base and 
joins the facial artery.6,26,27 Conversely, photographs of arteriograms5,28,29 and illustrations 
derived therefrom9,30 show a superior labial artery that thins out at the inner side of the cleft 
nostril, whereas the superior alar branches connect laterally to the facial artery. Our 
intraoperative findings concur well with the arteriogram pattern. 
We consistently found an arterial branch at the inner side of the cleft nostril. The artery 
emerged on top of the dissected transverse nasalis muscle and was easily preserved after its 
course had been estimated. We speculate that preserving this artery weakens post-
operative cleft nostril contraction. 
The facial vascular pattern does not develop as a stepwise branching from proximal to distal. 
Rather, preferred routes in a territory are formed consequent to its hemodynamic need and 
are connected to supplying trunks from distal to proximal. The cleft might reduce the 
available options for alar connections to supplying trunks, which leads to a more uniform 
vascular pattern on the cleft side. This might explain why we consistently found an artery on 
the inner side of the cleft nostril. 
 
Summary and clinical interpretation 
We studied the arterial flow velocity and microcirculation in cleft lip. Contrary to the 
asymmetric vascular anatomy in cleft lips, we found no functional asymmetry. Our results 
support the current standard of cleft-lip repair that does not involve surgical anastomosis of 
the lip artery. 
While the blood circulation did not differ from that of controls in the late-postoperative 
period, we cannot assume that vascular function was normal in all aspects, especially with 
regard to its ability to support growth potential. We therefore advocate strict vascular 
preservation in cleft surgery. The complex relationship between vascular anatomy and 
physiology necessitates further in-vivo circulatory measurements to assess the optimal 
blood circulation for cleft surgery. 
The surgical vascular anatomy exhibited a high degree of uniformity, which simplifies its 
consideration in current cleft surgical techniques. This finding has been confirmed for the 
paramedian prolabial arteries and the transverse nasalis perforating artery. 
 
Conclusion 
The blood circulation in UCLP and BCLP patients remains balanced before and after surgery, 
and is comparable to the normal situation, with no sign of an intrinsic circulatory deficit or a 
need for surgical arterial anastomosis. The increased flow in the prolabium of BCLP patients 
indicates a strong hemodynamic need in this territory, compelling its vascular preservation. 
We consistently found a perforating artery on the superficial side of the transverse nasalis 
muscle. Whether or not the surgical preservation of this artery has any long-term benefit 
should be addressed in future studies. 
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Table 1. Arterial Blood Flow Velocity in Unilateral Complete Cleft Lip and Palate Patients 
    Measuring point 
Before lip repair 
(n = 13)1 
End of lip repair* 
(n = 11)2 
Late postoperative 
(n = 12)3 ANOVA of mean values 
Maximum Mean Maximum Mean Maximum Mean 
Superior labial artery        
    Commissur, C 304 (85) 118 (48)a,b 113 (32) 39 (13)a 242 (122) 84 (56)a,b 
F (5, 30)= 2.537, p<.05 
    Commissur, NC 193 (88) 79 (35)a,b 192 (108) 94 (59)a,b 296 (143) 129 (55)b 
    Cupid, C  150 (107) 73 (63) 103 (63) 48 (24) 101 (41) 56 (37) 
F (5, 46)= 1.689, ns 
    Cupid, NC 163 (65) 93 (51) 107 (48) 34 (18) 164 (98) 81 (53) 
    Tuberculum 146 (51) 88 (33) 111 (50) 50 (36) 145 (74) 80 (53) F (2, 23)= 1.792, ns  
Columella branch 138 (58) 67 (39) 90 (23) 21 (12) 122 (54) 66 (47) F (2, 23)= 2.272, ns 
Lateral nasal artery        
    Ala base, C 166 (61) 75 (50) 136 (59) 57 (24) 92 (31) 35 (12) 
F (5, 50)= 0.737, ns 
    Ala base, NC 128 (79) 54 (40) 156 (88) 72 (70) 65 (22) 21 (7) 
Data are mean (SD) values in cm/s. A continuous-wave Doppler device employing an 8-MHz probe was used. Within rows of symmetric or the same measuring 
points, means with different subscripts differ at p<0.05, according to Tukey’s multiple-comparisons test. 
* Same individuals as measured before lip repair. 
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1-3 Sample sex distribution and mean age (male/female, month, SD); 1(8/5, 13, 15), 2(6/5, 13, 16), 3(11/1, 16, 9) 
3 Months after lip repair (mean, SD); (8, 4) 
C, cleft side; NC, non-cleft side  
42 
 
Table 2. Microcirculatory Flow in Unilateral and Bilateral Complete Cleft Lip and Palate Patients and Controls 
    Measuring point 
Control Before lip repair End of lip repair* Late postoperative 
    ANOVA  
(n = 22)1 
UCLP 
(n = 29)2 
BCLP 
(n = 11)3 
UCLP 
(n = 27)4 
BCLP 
(n = 10)5 
UCLP 
(n = 33)6 
BCLP 
(n = 20)7 
Lateral lip, C / left 95 (33)a,b,c,d 89 (35)a,b,c,d 113 (59)a,b,c,d 67 (69)a,b 54 (52)a,b,c 112 (77)b,c,d 130 (99)c,d 
F (13, 288)= 3.868, p< .001 
Lateral lip, NC / right 95 (51)a,b,c,d 92 (60)a,b,c,d 98 (58)a,b,c,d 47 (35)a 64 (35)a,b,c,d 90 (58)a,b,c,d 143 (80)d 
Cupid, C / left 104 (43)a,b,c,d 93 (68)b,d 184 (81)c 60 (54)a,d 72 (47)a,b,d 117 (76)a,b,c,d 98 (70)a,b,c,d 
F (13, 247)= 3.679, p<.001 
Cupid, NC / right 128 (52)b,c 89 (58)a,b,d 128 (40)a,b,c, 62 (46)a,d 75 (48)a,b,d 111 (40)a,b,c,d 108 (75)a,b,c,d 
Philtrum / Prolabium 119 (52)a,b 116 (44)a,b 216 (87)d 78 (55)b,c 172 (87)a,b,d  120 (50)a,b 169 (83)a,d F (6, 125)= 6.596, p<.001 
Columella 122 (38) 119 (59) 130 (36) 95 (65) 129 (50) 122 (66) 119 (52) F (6, 145)= 1.148, ns 
Ala, C / left 104 (47)a 98 (38)a 88 (11)ab 70 (29)a,b 81 (68)a,b 72 (39)a,b 86 (55)a,b 
F (13, 238)= 2.589, p<0.01 
Ala, NC / right 77 (24)a,b 97 (43)a 100 (44)a,b 51 (21)b 91 (23)a,b 83 (45)a,b 70 (38)a,b 
Data are mean (SD) values in arbitrary units. The approximate optical measurement depth was 0.88 mm on the columella and 1.41 mm at all other 
points. Within rows of symmetric or the same measuring points, means with different subscripts differ at p<0.05, according to Tukey’s multiple-
comparisons test. 
*Same individuals as measured before lip repair. 
1–7 Sample sex distribution and mean age (male/female, month, SD); 1(15/7, 62, 36), 2(18/11, 9, 6), 3(9/2, 14, 20), 4(17/10, 9, 6), 5(8/2, 14, 21), 
6(22/11, 46, 47), 7(14/6, 41, 36) 
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6,7 Months after lip repair (mean, SD); 6(28, 33), 7(31, 33) 
C, cleft side; NC, non-cleft side; UCLP, unilateral complete cleft lip and palate; BCLP, bilateral complete cleft lip and palate  
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Table 3. Post-capillary Haemoglobin Oxygenation in Unilateral and Bilateral Complete Cleft Lip and Palate Patients and Controls 
    Measuring point 
Control Before lip repair End of lip repair* Late postoperative  
    ANOVA   
(n = 22)1 
UCLP 
(n = 29)2 
BCLP 
(n = 11)3 
UCLP 
(n = 27)4  
BCLP 
(n = 10)5 
UCLP 
(n = 33)6 
BCLP 
(n = 20)7 
Lateral lip, C / left 67 (11)a,c 59 (11)a,c 61 (9)a,b,c 48 (21)b 53 (22)b,c 66 (17)a,c 65 (14)a,c 
F (13, 288)= 6.777, p<.001 
Lateral lip, NC / right 66 (16)a,c 54 (12)b,c 56 (6)a,b,c 44 (15)b 39 (23)b 63 (17)a,c 68 (12)a,c 
Cupid, C / left 54 (18)a,b
 54 (14)a,b 71 (12)a 50 (22)a,b 58 (18)a,b 63 (15)a,b 65 (16)a,b 
F (13, 245)= 2.845, p<.001 
Cupid, NC / right 62 (12)a,b 47 (12)b 63 (10)a,b 48 (25)a,b 57 (24)a,b 57 (12)a,b 62 (14)a,b 
Philtrum / Prolabium 63 (12) 56 (15) 61 (20) 52 (21) 69 (18) 61 (13) 60 (15) F (6, 125)= 1.176, ns 
Columella 44 (12)a,b 43 (20)a,b 51 (14)a,b 43 (19)a,b 65 (22)a 41 (17)b 45 (13)a,b F (6, 142)= 2.101, ns 
Ala, C / left 56 (15) 53 (13) 62 (9) 50 (17) 42 (11) 47 (15) 51 (15) 
F (13, 237)= 1.111, ns 
Ala, NC / right 51 (14) 50 (14) 55 (10) 46 (20) 51 (17) 47 (17) 52 (16) 
Data are mean (SD) values expressed as a percentage of the total haemoglobin. The approximate optical measurement depth was 0.88 mm on the columella 
and 1.41 mm at all other points. Within rows of symmetric or the same measuring points, means with different subscripts differ at p<0.05, according to Tukey’s 
multiple-comparisons test. 
*Same individuals as measured before lip repair. 
1–7 Sample sex distribution and mean age (male/female, month, SD); 1(15/7, 62, 36), 2(18/11, 9, 6), 3(9/2, 14, 20), 4(17/10, 9, 6), 5(8/2, 14, 21), 6(22/11, 46, 47), 
7(14/6, 41, 36) 
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C, cleft side; NC, non-cleft side; UCLP, unilateral complete cleft lip and palate; BCLP, bilateral complete cleft lip and palate 
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Table 4. Microcirculatory Haemoglobin Level in Unilateral and Bilateral Complete Cleft Lip and Palate Patients and Controls 
    Measuring point 
Control Before lip repair End of lip repair* Late postoperative 
    ANOVA  
(n = 22)1 
UCLP 
(n = 29)2 
BCLP 
(n = 11)3 
UCLP 
(n = 27)4 
BCLP 
(n = 10)5 
UCLP 
(n = 33)6 
BCLP 
(n = 20)7 
Lateral lip, C / left 76 (4)d 74 (6)b,c,d 72 (9)a,b,c,d 72 (8)a,b,c,d 66 (10)a 76 (8)d 78 (6)d 
F(13, 288)= 5.748, p<.001 
Lateral lip, NC / right 77 (5)d 72 (6)a,b,c,d 71 (6)a,b,c,d 69 (5)a,b,c 68 (8)a,b 75 (7)c,d 79 (5)d 
Cupid, C / left 75 (6) 72 (6) 77 (4) 77 (8) 73 (7) 75 (9) 76 (5) 
F(13, 247)= 1.299, ns 
Cupid, NC / right 77 (6) 73 (8) 71 (9) 72 (10) 76 (8) 75 (6) 75 (7) 
Philtrum / Prolabium 77 (6)a,b 73 (8)a 78 (9)a,b 74 (11)a 86 (9)b 76 (7)a,b 77 (5)a,b F (6, 125)= 2.510, p<.05 
Columella 58 (8)a,b 51 (7)c 61 (8)a,b 60 (9)a 62 (9)a,b 53 (9)b,c 57 (7)a,b,c F (6, 144)= 5.006, p<.001 
Ala, C / left 75 (5) 71 (7) 72 (4) 73 (7) 67 (5) 73 (6) 75 (4) 
F (13, 238)= 1.592, ns 
Ala, NC / right 74 (5) 71 (7) 71 (9) 69 (6) 72 (4) 73 (6) 73 (6) 
Data are mean (SD) values in arbitrary units. The approximate optical measurement depth was 0.88 mm on the columella and 1.41 mm at all other 
points. Within rows of symmetric or the same measuring points, means with different subscripts differ at p<0.05, according to Tukey’s multiple-
comparisons test. 
*Same individuals as measured before lip repair. 
1–7 Sample sex distribution and mean age (male/female, month, SD); 1(15/7, 62, 36), 2(18/11, 9, 6), 3(9/2, 14, 20), 4(17/10, 9, 6), 5(8/2, 14, 21), 
6(22/11, 46, 47), 7(14/6, 41, 36) 
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C, cleft side; NC, non-cleft side; UCLP, unilateral complete cleft lip and palate; BCLP, bilateral complete cleft lip and palate  
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Abstract 
Optimising the relation of outcome quality and burden of care is a challenge in cleft lip 
and palate treatment. We analyse the long-term outcome after one-stage cleft repair 
to assess its benefits and limitations as an alternative cleft care model. 
Lip repair, two-flap palatoplasty and cortico-cancellous alveolar bone graft was 
performed at 6 month of age. Thirty-three patients from 6–18 years were divided into 
three age groups (6-10.5y, 12-13.5y, 15-17.6y) and compared to mean outcome data 
from the Eurocleft centers and to Cephalometric Standards of healthy individuals. 
Fifteen of 33 patients complied for nasalance measurements. 
The maxillary protrusion (SNA) and intermaxillary relation (ANB) in the one-stage 
groups differed significantly from healthy individuals but not from the corresponding 
Eurocleft means. The Bergland Score for alveolar ossification was grade I or II in 61%, 
and grade III in 15%; 24% underwent secondary alveolar bone grafting. No palatal 
fistulae occurred and the nasalance did not differ significantly from that of healthy 
controls. On an average, each patient got the primary surgery and one secondary 
procedure, which was half as much compared to multi-stage procedures. 
The one-stage procedure led to significant growth disturbance however the degree of 
growth disturbance was similar to the mean values of multi-stage procedures obtained 
in the Eurocleft study. Primary alveolar bone grafting led to inconsistent alveolar 
ossification and was suspected to interfere with anterior maxillary growth – it has been 
abandoned. The patients benefited from half the number of surgical steps compared 
to multi-stage procedures. 
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Introduction 
Optimizing the relation between outcome quality and burden of care is a continuous 
challenge in cleft lip and palate treatment. Facing this challenge, all unilateral 
complete cleft lip and palate (UCLP) patients received a one-stage cleft repair at 
6 months of age, combined with primary alveolar bone grafting, between 1991 and 
2002.1  
There are several ways to close a unilateral cleft in one procedure. The main 
differences are (1) single2,3 or double layer1 hard palate closure, (2) hard palate repair 
with two-flap palatoplasty1 or V-Y pushback,4 or lateral releasing incisions,2 (3) cranial 
pedicled1,3 or caudally pedicled2,5 vomer flap, (4) alveoplasty4 or primary alveolar bone 
graft,1 and (5) whether the one-stage repair is applied in all cleft patients1,5 or only in 
those with narrow clefts.3 Each of these variations might influence the outcome of 
growth, occlusion, alveolar ossification, nasalance, and number of subsidiary 
procedures divergently. We therefore assessed all these outcome parameters jointly. 
Alveolar bone grafting at the time of lip repair and early two-layer hard-palate closure 
have been reported to result in unfavourable growth effects.2 Therefore, in our one-
stage repair evident growth retardation must be feared. 
In addition to growth and speech, the third aspect under which a cleft protocol should 
be approached is the burden of care; whereof the number of surgeries is one aspect.6,7 
We assessed the long-term benefits and limitations of one-stage repair combined with 
primary alveolar bone grafting in all patients between 1991 and 2002 who had had 
unilateral complete cleft lip and palate (UCLP) repair at 6 month of age.1 
 
 
Patients and Methods 
 
Patients 
From 1991 until 2002 when the surgeon retired, 53 nonsyndromic complete UCLP 
patients were operated upon. Of these, 33 participated in the study (age range 
6-18 years (Table 1), 8 had moved away, and 12 did not participate because of the 
extra effort required. 
Photographs, cephalograms, orthopantomograms, and dental casts were taken, and 15 
patients also participated in a nasalance assessment. All patients gave written 
informed consent, and the study was approved by the local ethics committee (EK 
256/06). 
 
Surgery 
All patients had a palatal obturator after birth to keep the alveolar segments in place 
and to facilitate feeding. All patients were operated by the same surgeon using a one-
stage cleft repair comprising two-flap palatoplasty and a cortico-cancellous alveolar 
bone graft from the rib. A vestibular mucoperiosteal flap from the lesser maxillary 
segment was advanced to cover the alveolar bone graft.1  
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Methods 
The classification of three age groups (6-10.5y, 12-13.5y, 15-17.6y) and the 
cephalometric parameters for hard- and soft-tissue analysis were chosen to allow 
comparability to the Eurocleft Study.8 The cephalograms were analysed digitally using 
OnyxCeph Software (Image Instruments, Chemnitz, Germany). Landmark identification 
was conducted jointly by two raters. Ten randomly selected radiographs were analysed 
again by the same team after a time interval of at least 1 month. Means and standard 
deviations of the differences between both skeletal ratings were calculated. 
The cephalometric mean values from all centers which completed the Eurocleft study 
(centers A, B, D, E, F) were used as comparative values of a variety of multi-stage 
procedures.8 The comparative values of healthy individuals are based on the 
Cephalometric Standards.9 An analysis of variance with Games-Howell post-hoc 
comparisons was performed to detect differences between three groups. Student’s t-
tests or Welch-tests were performed to detect differences between two groups. 
The EUROCRAN Index was used to quantify an occlusal rating on dental casts.10 The 
presence of permanent lateral incisors on the dental casts and orthopantomograms 
was noted. Alveolar bone ossification was evaluated using the Bergland Score.11 Four 
sentences without nasal consonants12 were recorded with the Nasometer II 64000 (Kay 
Elemetrics Corporation, Lincoln Park, New Jersey, USA). The same Nasometer analysis 
was repeated in a matched control group of healthy individuals. 
The number and type of subsidiary operations were retrieved from the patients’ 
documentation and confirmed by the parents. Comparative data from multi-stage 
procedures were used from the Eurocleft Study.13 
 
 
Results 
The 33 patients were divided into three age groups of 15, 7, and 11 patients each 
(Table 1). 
Cephalometric skeletal values are listed in Table 2. The maxillary protrusion (SNA) and 
intermaxillary relation (ANB) in the intermediate and oldest one-stage groups differed 
significantly from healthy Cephalometric Standards but did not differ significantly from 
the corresponding Eurocleft means. The maxillary plane angle and the midface-to-
total-height proportion differed significantly between the one-stage group and the 
Eurocleft mean in the youngest age group, but not in the intermediate and oldest age 
groups. The mean and standard deviation of the differences between two skeletal 
ratings are listed in the legend of Table 2. 
The soft-tissue maxillomandibular relationships in all one-stage groups did not differ 
significantly from the corresponding Eurocleft mean (Table 3). In all one-stage groups, 
the midface-height-to-total-facial-height ratio was significantly higher than the 
Eurocleft mean, thus closer to normal values. 
The lateral incisors were absent on the cleft and noncleft sides in 66.7% and 45.5% of 
cases, respectively (Table 4). The dental arch relationship, according to the EUROCRAN 
Index, in the youngest and intermediate age groups had a similar distribution: about 55 
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% had grade 1 or 2 (class I apical base relationship), and about 45 % had grade 3 or 4 
(edge-to-edge or class III apical base relationship). In the oldest age group, 36.5% had 
grade 1, none had grade 2, and 63.5% had grade 3 or 4 (Table 4) 
An alveolar cleft ossification (Bergland Score) of grade I or II was found in 60.6%, and 
of grade III in 15.2%; secondary alveolar bone graft was necessary in 24.2% of the total 
sample using an autologous cancellous bone graft from the iliac crest. 
The mean nasalance values in the one-stage group (M = 12.13, SD = 8.68) did not differ 
significantly from an age- and sex matched healthy control group (M = 11.27, SD = 
5.05): unpaired t test with Welch’s correction for unequal variances, t(94) = 0.67, 
p>.05. 
From the total sample of 33 patients, 20 (61%) underwent a subsidiary procedure 
(Table 5). The total number of surgeries in the one-stage cohort (2.1) was about half of 
that from centers with multi-stage procedures (3.5 to 4.8). No palatal fistulae occurred 
in the cohort, no orthognathic surgery was performed. 
 
 
Discussion 
 
Comparison with multi-stage procedures 
In 72% from 201 European cleft centers the teams use 2 surgeries to close the lip, and 
hard and soft palates.7 Two-thirds of the teams complete this treatment within the 
patient’s first year of life. It seems reasonable to consider combining both surgeries. 
The maxillary protrusion (SNA, ANB) and the vertical facial development in all one-
stage age groups did not significantly differ from the mean values of the Eurocleft 
centers. A detailed comparison with the different centers of the Eurocleft Study 
revealed that the SNA lies between the Eurocleft values for the youngest age group, 
equal to the best value for the intermediate age group, and 0.4º inferior to the lowest 
value for the oldest age group.8 
The mean Eurocleft SNA value is about the same as that determined for delayed hard-
palate closure samples at an intermediate age (75.3° vs 75.5°)8,14,15 and oldest age 
(74.4° vs 74.3°)8,14 and is therefore quite representative for a variety of multi-stage 
procedures. Further the SNA value is robust against the error of landmark 
identification,12 with the mean difference between two ratings of -0.4° (SD 1.4) in our 
sample (Table 2). 
However, growth generalisation cannot be based solely on the SNA value.15 Some 
cephalometric changes in cleft patients are due to the malformation itself, some occur 
after any kind of repair, and some are truly related to the protocol and surgeon. 
Unwanted protocol-dependent growth patterns are (1) reduced anterior maxillary 
height (2) reduced posterior maxillary height with clockwise rotation of the maxilla, 
and (3) midface retrusion due mainly to reduced maxillary length. The oldest one-stage 
group did not differ significantly from the Eurocleft mean in terms of these protocol-
dependent growth patterns, but a nonsignificant maxillary shortening was noted. One 
contributing factor might be the high rate of missing lateral incisors in our sample.16 
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However, since maxillary length can be close to normal if the alveolar nasal floor has 
not been repaired at all,15 the primary alveolar bone grafting needs to be judged 
critically. 
Furthermore, it is suspected that primary alveolar bone grafting interferes with 
anterior maxillary growth, since of the nine patients who exhibited the best occlusal 
relationships (EUROCRAN grade 1) six of them experienced severe resorption of the 
graft after surgery. Thus, contrary to the original assumption, it seems that minimal 
and not maximal stabilisation of the alveolar segment leads to favourable occlusion. 
We thus abandoned obturators to keep the alveolar segments in place before surgery 
and abandoned primary alveolar bone grafting in 2003. In addition, the favourable 
occlusion in these cases suggests, that the surgical trauma per se does not necessarily 
compromise growth zones. 
The primary alveolar bone graft was also abandoned following a regraft rate of 24%. In 
other protocols, the primary alveolar bone graft is placed in a separate operation after 
lip repair, when the alveolar cleft has narrowed.17 However, this can be associated 
likewise with a regraft rate of 25% and additionally with a fistula rate of 26.8%.17 In 
contrast, we did not encounter palatal fistulae, despite a wide mean anterior cleft 
width of 16.8 mm at the time of cleft repair. We assume that the primary alveolar 
bone graft together with two-layer palatal closure prevented the formation of anterior 
palatal fistulae. 
The orthognathic surgery rate in UCLP samples from the literature ranges widely from 
about 20% to 45%.17-19 The rates are difficult to compare, since they reflect not only 
growth outcome but also differences in the patients’ demands, surgical cut-offs, and 
health-care funding. In the oldest group, we expect a 45% orthognathic surgery rate, 
while in the youngest group, a 20% orthognathic surgery rate is highly probable, since 
20% have an SNA below –1° at 6 years.20 Thus, we expect an orthognathic surgery rate 
that is in the upper range of that for other multi-stage procedures. Figure 1 and 2 
shows the same patient, as preoperatively shown in the initial publication of the 
surgical technique from 1996.1 
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Fig. 1, 2. Facial profile and occlusion at 18 years 8 months of the same patient who was shown 
in the initial publication about the one-stage surgical technique in 1996.1 He had 
velopharyngoplasty as a subsidiary operation at the age of 8 years 9 months and will have 
orthognathic surgery to complete the treatment (photograph published with the patient’s 
consent). 
 
Comparison with other one-stage procedures 
De Mey et al. reported on a one-stage procedure with a cranial-pedicled vomer flap.3 
They excluded 48% of patients from the procedure due to their posterior cleft width 
being >11 mm at the time of surgery. Brusati also restricted the one-stage procedure 
to those with a maximal 10-mm posterior cleft width (keynote lecture, 9th European 
Craniofacial Congress 2011). In the study of De Mey et al., the growth results (SNA and 
ANB) at 10 and 15 years of age were greater than those found in the present study.3 
Fifty-two percent of our sample had a posterior cleft width of >11 mm at the time of 
surgery, which might largely explain the different growth outcomes. A palatal cleft 
width at surgery of 10% or less of the surrounding palatal surface has been suggested 
as a favourable growth predictor.21 In turn, De Mey et al. encountered a fistula rate of 
42%, of which two-thirds needed a subsidiary operation.3 This diminishes the benefit 
of a reduced number of surgeries. 
Fudalej et al.5 and Kulewicz et al.2 reported on one-stage repair in an unrestricted 
sample using a caudal-pedicled vomer flap and lateral releasing incisions. They 
encountered as well a fistula rate of 46% (poster, 9th European Craniofacial Congress 
2011). Their sample of 9.5- to 14.7-year-old patients yielded SNA (75.3° vs 76.3°) and 
ANB (0.8° vs –0.2°) values similar to those reported herein, as well as a similar mean 
EUROCRAN dental arch relationship grade (2.58 vs 2.57).5 Thus, despite alveolar bone 
grafting and double-layer palatal closure in our sample, the growth outcome was 
comparable to that reported for this less extensive procedure. We assume that limiting 
the one-stage procedure to cases with a narrow cleft width influences the growth 
outcome more strongly than does the variation in surgical procedure. 
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The speech quality allowed all patients to engage in normal schooling with healthy 
peers. The velopharyngeal insufficiency (VPI) correction rate was 12%, which is close to 
that reported for early combined hard- and soft-palate repair in multi-stage procedure 
(6–11.0%).22 
A main objective of the one-stage concept was to reduce the number of surgeries, as 
they are considered to be a stressor for the family and to make a successful coping 
more difficult.1 Recent evidences encourage this effort, since the number of subsidiary 
operations was found to negatively correlate with the child’s physical well-being.23 
Further, multiple anesthetics before age 4 years, but not single anesthetics, were 
found to be a significant risk factor for development of learning disabilities.24 Despite 
some patients will undergo additional secondary procedures in the future, we expect 
to finish the treatment below a mean number of 3 anaesthesias per patient. 
 
 
Conclusion 
The one-stage procedure led to significant growth disturbance however the degree of 
growth disturbance was similar to the mean values of multi-stage procedures obtained 
in the Eurocleft study. Primary alveolar bone grafting led to inconsistent alveolar 
ossification and was suspected to interfere with anterior maxillary growth – it has been 
abandoned. The patients did ultimately benefit from a reduced number of surgical 
steps, since the total number of surgeries was halved compared to multi-stage 
procedures. 
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Table 1. Unilateral complete cleft lip and palate study groups after one-stage repair 
 
    Variable 
Total 
(n = 33) 
Group 1 
(n = 15) 
Group 2 
(n = 7) 
Group 3 
(n = 11) 
Male / female 
Cleft right / left 
Mean (SD) age at study (years) 
Mean (SD) age at repair (months) 
Soft tissue lip band 
Mean (SD) anterior width of cleft (mm)a 
Mean (SD) posterior width of cleft (mm)b 
22 / 11 
14 / 19 
13 (4) 
7 (2) 
7 
17 (4) 
13 (4) 
11 / 4 
6 / 9 
9 (2) 
6 (1) 
3 
18 (5) 
14 (4) 
3 / 4 
4 / 3 
13(1) 
6 (1) 
1 
15 (4) 
14 (4) 
8 / 3 
4 / 7 
16 (1) 
7 (2) 
3 
17 (3) 
10 (4) 
Data are mean (SD) and rounded up to whole numbers. 
a Distance at cleft nostril at time of one-stage repair. 
b Distance at posterior nasal spine at time of one-stage repair. 
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Table 2. One-stage cephalometric dentoskeletal values compared with the mean value from all centres that completed the Eurocleft study8 (centres A, B, D, E, 
and F) and normals (male and female values based on cephalometric standards9). Data are mean (SD). Angles are measured in degrees. 
Variable  
Group 1 p-value Group 2 p-value Group 3 p-value 
One-stage 
(n = 15) 
Eurocleft 
(n = 25) 
Normal 
 (n = 62) 
 One-stage 
(n = 7) 
Eurocleft 
(n = 25) 
Normal 
(n = 71) 
 One-stage 
(n = 11) 
Eurocleft 
(n = 25) 
Normal 
(n = 32) 
 
Age (years) 9 (1) 10 (1) 6 (0)  13 (1) 13 (1) 12 (0)  16 (1) 17 (1) 16 (0)  
Maxilla             
S-N-A 76 (4)
a
 77 (4)
a
 81 (3)
b
 <0.001 76 (4)
a
 75 (4)
a
 81 (4)
b
 <0.001 73 (6)
a
 74 (4)
a
 82 (4)
b
 <0.001 
S-N/ANS-PNS 14 (4)
a
 10 (4)
b
 6 (3)
c
 <0.001 10 (3) 9 (4) 7 (3) <0.05 8 (2)
a,b
 9 (4)
b
 8 (3)
a
 <0.01 
Mandible             
S-N-Pog 75 (4) 75 (4) 76 (3) <0.05 79 (5)
a,b
 76 (4)
b
 78 (4)
a
 <0.05 79 (3) 78 (4) 80 (4) 0.081 
S-N/Go-Gn 35 (4) 38 (5) 35 (5) 0.095 30 (7)
a
 37 (5)
b
 34 (5)
b
 <0.05 32 (5) 36 (6) 32 (4) 0.082 
Maxillomandibular             
A-N-B  3 (3) 3 (3) 5 (2) <0.05 –0.2 (3)
a
 0.9 (3)
a
 4 (2)
b
 <0.001 –3 (4)
a
 –1 (3)
a
 3 (2)
b
 <0.001 
ANS – PNS/ILs 103 (15) 99 (9) 101 (9) 0.166 106 (3)
a
 97 (6)
b
 112 (6)
c
 <0.001 110 (6)
a
 94 (7)
b
 112 (6)
a
 <0.001 
ILs/ILi 154 (12)
a
 145 (16)
a,b
 141 (14)
b
 <0.05 149 (6.4)
a
 141 (10)
b
 126 (10)
c
 <0.001 142 (8)
a
 137 (10)
a
 130 (12)
b
 <0.001 
Vertical             
N-ANS:N-Gn %  41 (2)
a
 42 (2)
b
 43 (5)
b
 0.071 43 (3)
a
 43 (2)
a
 45 (6)
b
 0.092 41 (2)
a
 42 (2)
a
 44 (7)
b
 <0.05 
Within each row of an age-group, means with different superscripts differ at the 0.05 level of significance according to Games-Howell post-hoc comparisons. 
Cephalometric dentoskeletal points used in the study:8 N, nasion (most anterior point of the frontonasal suture); S, sella, (centre of the sella turcica); A, 
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subspinale (deepest point on the anterior contour of the upper alveolar arch); B, supramentale (deepest point on the anterior contour of the lower anterior 
process); ANS, anterior nasal spine (apex of the anterior nasal spine); PNS, posterior nasal spine (intersection of nasal floor and posterior contour of the 
maxilla); pogonion (most anterior point on the mandibular symphysis); Go, gonion tangent point (point of intersection between the mandibular and ramus 
lines); Gn, gnathion (most inferior point on the mandibular symphysis); ILs, incisor line superior (axis of the upper incisors); ILi, incisor line inferior (axis of the 
lower incisors). Data are mean (SD) and rounded up to whole numbers.  
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Table 3. One-stage cephalometric values of soft tissue profile compared with the mean value from all centres that completed the Eurocleft study (centres A, B, 
D, E, and F)8. Data are mean (SD). Angles are measured in degrees. 
    Variable  
Group 1 p-value Group 2 p-value Group 3 p-value 
One-stage 
(n = 15) 
Eurocleft 
(n = 25) 
 One-stage 
(n = 7) 
Eurocleft 
(n = 25) 
 One-stage 
(n = 11) 
Eurocleft 
(n = 25) 
 
Age (years) 9 (1) 10 (1)  13 (1) 13 (1)  16 (1) 17 (1)  
Maxillomandibular          
ss-ns-sms  6 (3) 5 (3) 0.54  4 (3) 4 (3) 0.54 2 (3) 3 (3) 0.38 
sss-ns-pgs 5 (3) 4 (3) 0.45 1.6 (3.1) 3 (3) 0.64 0.3 (3) 1 (3) 0.54 
gs-sn-pgs 187 (7) 187 (6) 0.90 181 (7) 185 (6) 0.42 177 (5) 182 (8) 0.76 
Nasal profile          
gs-prn-pgs 150 (5) 151 (5) 0.40 146 (6) 149 (5) 0.094 149 (4) 147 (6) 0.83 
ns-unt/N-S 107 (4) 105 (4) 1.60 112 (5) 106 (4) 0.008 109 (6) 108 (5) 0.67 
ns-prn-sn 105 (6) 104 (6) 0.41 93 (8) 102 (5) 0.005 93 (4) 98 (5) 0.06 
nst-sn-ls  102 (11) 102 (12) 0.75 102 (8) 97 (15) 0.31 95 (12) 105 (13) 0.10 
Vertical          
ns-sn : ns-gns % 43 (2) 39 (2) 0.004 45 (2) 40 (2) 0.000 43 (2) 39(2) 0.000 
Cephalometric soft tissue profile points used in the study.8 gs, soft tissue glabella (most anterior point on soft tissue glabella); ns, soft tissue nasion (deepest 
point on frontonasal curvature); unt, upper nasal tangent point from ns; prn, pronasale (most prominent point on tip of the nose); nst, nasal septum tangent 
65 
 
point (anterior tangent point to tangent to the nasal septum through sn); sn, subnasale (deepest point in nasolabial curvature); sss, soft tissue subspinale (point 
of greatest concavity or convexity in midline of the upper lip); ls, labrale superius (most prominent point on prolabium of upper lip); sms, soft tissue 
supramentale (point of greatest concavity in midline of the lower lip); pgs, soft tissue pogonion (most prominent point on the chin); gns, soft tissue gnathion 
(soft tissue point overlying gn).  
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Table 4. Occlusal rating, lateral incisors status, and alveolar bone graft ossification after one-stage repair 
   Variable Total (n=33) Group 1 (n=15) Group 2 (n=7) Group 3 (n=11) 
Mean (SD) age (years) 13 (4) 8.5 (1.5) 12.5 (0.8) 16 (1) 
Occlusal EUROCRAN grade
a
     
1 27 20 29 37 
2 21 33 29 0 
3 24 33 0 27 
4 27.3 13 43 37 
Mean (SD) 2.5 (1.2) 2.4 (1.0) 2.6 (1.3) 2.6 (1.3) 
Missing lateral incisor     
Cleft side 67 73 43 73 
Non-cleft side 46 40 43 55 
Bilateral 36 33 29 46 
Primary alveolar bone graft     
With revision operation  24 13 43 27 
Without revision 76 87 57 73 
Ossification grade
b
     
I 42 33 43 55 
II 18 33 0 9 
III 15 20 14 9 
a
 EUROCRAN index of dental arch relation.10 Grade 1: apical base relation is class I or II. Both central incisors 
have positive overjet and overbite or there is considerably increased overjet with no overbite (note: it is grade 
2 if there are obvious dental compensations). Grade 2: apical base relation is class I. Non-cleft incisor is in 
positive overjet and overbite. Tilting or derotation of the cleft-side incisor would achieve stable overjet and 
overbite (note: it is grade 3 if there is moderate open bite). Grade 3: apical base relation is edge-to-edge or 
mild skeletal class III. One or both central incisors are edge-to-edge or in close anterior cross-bite. Tilting or 
derotation would not achieve stable overjet and overbite (note: it is grade 4 if there is severe open bite or if 
edge-to-edge position of incisor in class III is achieved by dental compensation). Grade 4: apical base relation is 
class III. Both central incisors are in anterior crossbite or one is in anterior crossbite with the other edge-to-
edge. 
b
 Ossification grade (Bergland score) of the alveolar bone graft measured on the panoramic radiograph. Two 
reference lines are drawn between the teeth on either side of the cleft, connecting the root tips and the 
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amelocemental junctions respectively. The distance between both lines defines the expected normal 
ossification height in the cleft area.11 Type I = normal height of interalveolar septum; type II = height of the 
interalveolar septum is at least 75% of the normal height; type III = interalveolar septum is less than 75% of the 
normal height.
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Abstract 
Cleft lip and palate are increasingly being detected by prenatal ultrasound, which has 
resulted in the requirement of a future surgical bone repair often being known before the 
baby is born. This raises the opportunity of using the patient’s own osteogenicity from 
umbilical cord mesenchymal cells, rather than discarding the umbilical cord at birth. 
However, the main limitation of this procedure is the growth of the cells under a fully 
defined and regulated protocol. The aim of this study was thus to address this limitation, 
whilst simultaneously evaluating the potential hurdles to therapy. 
Wharton’s-jelly (WJ)-derived mesenchymal stromal cells (WJMSCs) were isolated and 
expanded as a monolayer with defined serum-free medium. Osteoblastic differentiation was 
tested in WJMSCs as well as in entire WJ biopsy specimens. Serum-free cultured WJMSCs 
were included in hydroxyapatite granule–fibrin constructs, and without predifferentiation 
subcutaneously implanted into immune-incompetent mice. 
The isolation and expansion of WJMSCs was successful under serum-free conditions if the 
umbilical cords were processed within 48 h after birth (n=47). They expressed standard MSC 
markers but were negative for hematopoietic markers. Osteogenically differentiated 
WJMSCs and WJ biopsy specimens produced a mineralized extracellular matrix. The 
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expression of genes of osteoblastic lineage in these cells increased significantly (Hox-A10 and 
Runx2) and downstream osteogenic genes were up-regulated (OSX, OCN, ALPL, and BSP2). 
Although the WJMSCs formed a dense matrix with signs of osteoblastic differentiation 
adjacent to the granules in vivo, no mature bone tissue was found after 8 weeks. Whilst 
WJMSCs have osteogenic differentiation potential, the stumbling block to their clinical use is 
their transplantation, highlighting the difference between the in vitro and in vivo settings. 
Nevertheless, we have designed a fully defined osteogenic differentiation protocol, bringing 
a clinical protocol closer to regulatory approval. 
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Introduction 
Together with cardiac malformations, cleft lip and palate are the most frequent congenital 
malformation, and they require surgical repair within the first months of life. One in every 
500–700 newborns is affected by this condition, the severity of which varies widely. 
Reconstruction of the cleft in the maxilla (alveolar bone) commonly involves the use of 
autologous bone from the pelvic bone. This method has important shortcomings, including 
donor site morbidity and the reconstruction of the alveolar graft needing to be delayed to 
preteen age, since earlier grafting leads to growth inhibition and graft resorption. 
Consequently, an open gum ridge persists with adverse effects on speech and the teeth 
alignment. Thus, an autologous, tissue-engineered material with no donor site morbidity and 
that can be used early in life and complies with craniofacial bone growth and characteristics 
would provide multiple benefits to the patient. 
The choice of a distinct stem cell source, its osteogenic potential, the envisioned clinical use, 
and the laboratory protocol used to engineer tissue construct must be optimized to enable 
translation into clinical routine. Since cleft lip and palate malformations are most frequently 
diagnosed by a prenatal ultrasound [1], the autologous umbilical cord could serve as a 
noninvasive donor site for reconstruction of the cleft maxilla. Wharton’s jelly (WJ)-derived 
mesenchymal stromal cells (WJMSCs) reportedly exhibit a stronger osteogenic 
differentiation and greater bone-formation capacity compared to adipose-derived stem cells 
[2]. It was assumed that mesenchymal stromal cells (MSCs) from neonatal tissue are more 
naïve [3] and have an improved proliferation capacity [4], lifespan, and greater 
differentiation potential relative to bone marrow MSCs, which are derived from adult tissue. 
This makes WJMSCs a promising cell source for the correction of bone defects related to 
congenital malformations. 
However, one limitation is the absence of a method for growing the cells under a fully 
defined and regulated protocol. The present study was designed to address this limitation, 
while evaluating the potential hurdles to the therapeutic use of WJMSCs. The use of animal-
derived products considerably limits the feasibility to progress a validated cell culture 
protocol to clinical standards [5]. Regenerative concepts that work under fully defined 
conditions should thus be targeted. 
The challenge of rendering it clinically possible to use WJMSCs for autologous osteogenic 
tissue engineering for cleft lip and palate was addressed in the present study by evaluating 
the following three factors: 
1. Efficacy of the process of isolation, expansion, and storage of WJMSCs under fully defined 
conditions. 
2. In vitro osteoblastic differentiation of WJMSCs subsequent to cultivation under fully 
defined conditions or inside biopsy specimens. 
3. In vivo survival and tissue formation by naïve WJMSCs seeded in three-dimensional 
constructs, made under fully defined conditions. 
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Material and Methods 
 
Serum-free isolation, expansion, and cryopreservation of WJMSCs 
Human umbilical cords taken from consenting parents were stored at room temperature 
(RT) in phosphate-buffered saline (PBS) with penicillin-streptomycin-amphotericin B 
(100 U/ml, 100 µg/ml, and 0.25 µg/ml, respectively) and processed within 48 h after 
delivery. Adherent cells were isolated using the explant method [6]. Briefly, 2-mm-thick 
slices (Fig. 1A) were cut from the cord and 2.5-mm diameter biopsy specimens were taken 
from these slices, in between the two umbilical arteries and the vein (Fig. 1B, arrow heads). 
Isolation dishes (35 mm in diameter) were coated with a 4:1 mixture of PBS and 200 µg/ml 
collagen I–III from human placenta (ABCell-Bio, Paris, France), replaced with serum-free 
medium SPE-IV/EBM (ABCell-Bio) and four WJ biopsy specimens, and maintained in a 
humidified atmosphere with 5%CO2 and at 37°C. The medium contained clinical-grade 
human albumin and recombinant human growth factors. The cells were first passaged to a 
surface ratio of 1:3 to 1:5 after approximately 2 weeks using a cell-dissociation reagent that 
is free of animal- and human-derived components (TrypLE Select, GIBCO, Invitrogen, 
Carlsbad, CA, USA). 
A 5100 Cryo 1°C freezing container was used for cryopreservation (Nalgene, Rochester, NY, 
USA). Cryopreservation medium that was free of human and animal components (Cryo3 Ref. 
5617, Stem Alpha, St. Genis L’Argentière, France) was mixed with 10% dimethyl sulfoxide 
(DMSO; Ref. 8418, Sigma-Aldrich, St. Louis, MO, USA). WJMSCs in a confluent T25 flask, or 
alternatively three WJ biopsy specimens were suspended in 1.8 ml of cryopreservation-
DMSO solution. The box was stored at –80°C. After thawing, the WJ biopsy specimens and 
WJMSCs were cultured as described above. 
 
Osteogenic differentiation medium 
The osteogenic medium contained high-glucose Dulbecco Modified Eagle’s Medium (Ref. 
GIBCO 41966, Invitrogen) supplemented with 10% low-IgG fetal bovine serum (Ref. DE14-
870E, Lonza, Basel, Switzerland) and the following osteogenic factors: 10 mM β-glycerol 
phosphate (Ref. G9422, Sigma-Aldrich), 50 µg/ml ascorbic acid (Ref. A4403, Sigma-Aldrich), 
and 10 nM dexamethasone (Ref. D2915, Sigma-Aldrich). The osteogenic control medium was 
free of any osteogenic factors. The complete media were stored in the dark at +4°C and used 
within 1 month. The osteogenic differentiation was initiated at a culture confluency of 80%, 
and the medium was changed twice per week for 3 weeks. 
 
Constructs of WJMSCs, fibrin, and hydroxyapatite and in vivo test 
Serum-free isolated and expanded WJMSCS at passages 2 and 3 were combined with fibrin 
sealant (TISSEEL Kit, Baxter Innovations, Wien, Austria) and porous silicate-substituted 
hydroxyapatite (Actifuse Microgranules, ApaTech, Hertfordshire, UK). WJMSCs (3×106) were 
suspended in 30 µl of fibrinogen (40 mg/ml) and mixed with hydroxyapatite microgranules 
(60 mm3) that had been washed with serum-free medium. Coagulation was triggered by 
adding 30 µl of thrombin (12 IU/ml) and the preparation was incubated for 15 minutes at 
37°C and 5% CO2. Constructs without cells served as controls. For in vivo experiments, the 
constructs were implanted subcutaneously in the back of five female, 6-week-old immune-
73 
 
incompetent mice (CD-Nu/NU; Charles River, Wilmington, MA, USA). The experiment was 
conducted in duplicate and the mice were euthanized 8 weeks after implantation (animal 
permit No. 1797). 
 
Fluorescence-activated cell sorting 
Serum-free isolated and expanded WJMSCs were incubated for 30 minutes at 4°C with 
fluorochrome-conjugated antibodies raised against the indicated proteins or an isotype 
control (Table 1). The cells were analyzed using fluorescence-activated cell sorting with the 
aid of a FACSCanto flow cytometer and software, by collecting 10,000 events (BD 
Biosciences, San Jose, CA, USA). 
 
Quantitative real-time polymerase chain reaction 
Serum-free isolated and expanded WJMSCS were expanded for 3 weeks in osteogenic 
medium and in control medium. Total RNA (4 µg) was used in the reverse transcription to 
synthesize 4 µg of cDNA (high-capacity cDNA reverse transcription kit, Invitrogen). The 
reaction was carried out in a thermal cycler TC-512 (Techne, Minneapolis, MN, USA). The 
template was 100 ng of cDNA in the presence of 0.25 μl of forward and reverse gene-specific 
primers (Table 2), and 10 μl of EXPRESS SYBR GreenER qPCR Supermix Universal (Invitrogen). 
The amplifications were performed on Mastercycler ep realplex2 (Eppendorf, Hamburg, 
Germany). The relative gene expression levels were calculated as 2-ΔΔCt using four samples 
for every t-test, and three housekeeping genes in replicates [7]. 
 
Labeling and staining 
The viability of the cells was checked with a live-dead assay (Ref. L3224, Invitrogen); viable 
cells exhibit calcein green cytoplasmic fluorescence and the nuclei of dead cells exhibit red 
fluorescence. WJMSCs were fixed with 4% paraformaldehyde (Ref. HT5011, Sigma-Aldrich) 
for 10 minutes. Alizarin red stain was prepared fresh (20 mg/ml), filtered, and then left for 
2 minutes on the cells. The OsteoImage mineralization assay was used for specific green-
fluorescence labeling of the hydroxyapatite (Ref. PA-1503, Lonza). 
In-vitro-differentiated WJMSC samples were fixed in alcohol-formol acetic acid for 24 h at 
RT, decalcified, and then dehydrated in acetone and xylene baths to prepare them for 
paraffin embedding; they were then sliced at 5 μm. The sections were stained with a 
solution of hematoxylin of Harris, eosin, and safranin. Von Kossa staining was performed in 
5% silver nitrate under ultraviolet light with 2% sodium thiosulfate, followed by 
counterstaining with hematoxylin of Mayer. 
The implanted constructs were excised as a single piece, fixed in 1% paraformaldehyde, and 
decalcified in EDTA-based decalcification solution for 2 weeks. The decalcified samples were 
embedded in paraffin and then sectioned at 7 μm. After being subjected to a conventional 
dewaxing and rehydration sequence, the sections were stained with either hematoxylin and 
eosin or Masson’s trichrome (Ref. 361350, Reactifs RAL, Martillac, France). Cells of human 
origin were identified in the large constructs implanted in rats by staining the sections as 
described previously for human-specific Alu sequences with the aid of a ZytoFast CMV 
chromogenic in situ hybridization kit (Zytovision, Bremerhaven, Germany) [8]. 
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Immunohistochemistry 
The slides were incubated overnight at 4°C with polyclonal anti-BSP2 antibodies (Ref. ALX-
210-312, Enzo, Farmingdale, NY, USA), monoclonal anti-alpha smooth muscle actin (α-SMA; 
Ref. MCA1905HT, AbD Serotec, Oxfordshire, UK), or anti-collagen I or V antibodies (Refs. 
20111 and 20511, Novotec, Lyon, France), diluted in PBS-BSA 3% to 1/100, 1/1000, 1/1000, 
and 1/500, respectively. Secondary antibodies were applied (Ref. K4002 and K4000, Dako, 
Baar, Switzerland) and precipitated by diaminobenzidine (Ref. K3468, Dako). Counterstaining 
was performed with Mayer’s hematoxylin. 
 
 
Results 
Isolation, expansion, and storage of serum-free WJMSCs 
Isolation of WJMSCs from biopsy specimens of human umbilical cord always succeeded 
(n=47) if processed within 48 h after delivery (Fig. 1A,B). Although most of the samples 
(n=31) were from spontaneous deliveries rather than from cesarean sections (n=16), no 
bacterial or fungal contamination occurred. After 1 week, about half of all WJ biopsy 
specimens had condensed and the emigration of spindle-shaped cells had commenced 
(Fig. 1C). After 2 weeks, a dense layer of regular spindle-shaped cells had formed (Fig. 1D). 
 
Fig 1. Isolation of WJMSCs. (A) A 2-mm-thick slice of human umbilical cord. (B) WJ biopsy specimens 
of 2.5 mm in diameter (arrow heads) are taken using a skin biopsy tool connected to a 1 ml syringe. 
(C) Viability assay of cell outgrowth from the WJ biopsy specimens after 1 week. (D) After 2 weeks, a 
dense cell layer surrounds the biopsy specimens. (A, B; increments on the scale are millimeters) 
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In vitro, the mean±SD number of WJMSCs was 121,600±72,519 per 35-mm diameter dish at 
the first passage and 1.1±0.6×106 per confluent T25 flask at the second passage. Vials 
containing WJMSCs at passage 1 or fresh WJ biopsy specimens were stored for more than 
1 year at –80°C. After thawing, the WJMSCs and WJ biopsy specimens exhibited identical 
light-microscopic morphological appearances and expansion or isolation behaviors as their 
fresh counterparts (data not shown). 
 
Surface markers of serum-free isolated WJMSCs 
The surface marker expression of the WJMSCs was analyzed after isolation, cryopreservation 
for 1 month at passage 1, and re-expansion in serum-free medium to passages 3–5. The 
donors were the same as for the in vivo experiments. WJMSCs expressed standard MSC 
markers but were negative for hematopoietic markers (Fig. 2). WJMSCs expressed CD73, 
CD44, CD13, CD90, CD10, HLA-ABC, CD105, and CD166 but not or to a very low extent 
CD106, CD15, CD31, CD34, CD45, HLA-DR, and CD133. This spectrum of marker expression is 
typically known from MSCs derived from adipose tissue and bone-marrow (Table 3). 
 
Fig. 2. Mean±SD values of flow cytometric expression of surface markers in WJMSCs after 
isolation, cryopreservation, and expansion in fully defined media (n=5; passages ≤5): CD73, 
100±0%; CD44, 100±0%; CD13, 100±0%; CD90, 100±0%; CD10, 100±0.1%; HLA-ABC, 99.8±0.1%; 
CD105, 99.7±0.3%; CD166, 98.0±1.7%; CD106, 7.3±2.6%; CD15, 6.8±1.9%; CD31, 6.1±3.6%; C34, 
3.4±1.4%; CD45, 1.7±0.8%; HLA-DR, 0.9±0.3%; and CD133, 0.1±0.2%. 
 
In vitro monolayer osteogenic differentiation of WJMSCs 
Serum-free isolated and expanded WJMSCs exhibited a high cell viability after 3 weeks of 
osteodifferentiation as well as in controls (Fig. 3A,D). In contrast to the controls (Fig. 3E,F), 
the osteodifferentiation samples exhibited mineralization, positive for hydroxyapatite 
staining with Alizarin red and OsteoImage (Fig. 3B,C). 
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Fig. 3. Serum-free isolated and expanded WJMSCs after 21 days of differentiation with (A–C) 
and without (D–F) osteogenic factors, showing equally high viability (A). Positive staining for 
hydroxyapatite using Alizarin (B) and OsteoImage (C) in the differentiation group and negative 
staining in the control group (E, F). 
Since the histology of the monolayer of osteodifferentiated WJMSCs exhibited osteogenic 
commitment, the osteogenic transcription profile was analyzed further. The expressions of 
osteogenic downstream genes increased after 3 weeks of osteodifferentiation. The increase 
was significant for the early downstream genes RUNX2 and Hoxa10, and a non-significant 
trend was observed for OSX, ALPL, OCN, and BSP2 (Fig. 4). The STAT3 of the JAK-STAT 
pathway was significantly up-regulated and the WNT signaling cascade was inhibited by 
significant up-regulation of the WNT antagonist DKK1 and a consecutive decrease in CTNNB, 
the downstream component of the canonical WNT signaling pathway (Fig. 4). 
 
77 
 
 
Fig. 4. Transcription profile of serum-free isolated and expanded WJMSCs after 21 days of 
differentiation with osteogenic factors (gray bars), presented as mean and SD values of the 
relative change in gene expression compared to the control condition without osteogenic 
factors (black bars). Transcription profile of controls are normalized to –1 (n=4; passages ≤5). 
Gene, relative change, p value: HOX-A10, 23.1, p<0.04; OSX, 17.9, p<0.16; STAT3, 6.8, p<0.005; 
BGLAP, 6.6, p<0.19; RUNX2, 4.7, p<0.005; ALPL, 4.3, p<0.21; IBSP, 4.0, p<0.58; DKK1, 2.9, 
p<0.01; and CTNNB-1, –1.5, p<0.65. 
 
In vitro osteogenic differentiation of WJ biopsy specimens 
Since WJ itself is composed of collagen I, as with bone, the direct use of WJ biopsy 
specimens itself as a scaffold for osteodifferentiation is appealing and was therefore tested 
for such. The osteodifferentiated WJ biopsy specimens (Fig. 5A), but not controls (Fig. 5D), 
exhibited peripheral hematoxylin-positive staining after 3 weeks, presumably corresponding 
to acidic mucopolysaccharides, like in bone matrix. At these sites hydroxyapatite deposits 
were confirmed by von Kossa (Fig. 5B) and OsteoImage staining, respectively (Fig. 5C), 
whereas it was absent in controls (Fig. 5E,F). In every donor, 80% of the differentiated WJ 
biopsy specimens exhibited such calcifications. 
78 
 
 
Fig. 5. WJ biopsy specimens after 21 days of in vitro differentiation with (A–C) or without 
osteogenic factors (D–F). (A) Basophilic granular staining (HES; Harris, eosin, and safranin) of 
the extracellular matrix in the periphery of differentiated samples, indicating calcifications. (B) 
Von Kossa stain confirming mineralization in the basophilic region. (C) Mineralization assay on 
native WJ biopsy specimens showing peripheral net-like hydroxyapatite staining on 
osteodifferentiated samples. Note the absence of contiguous mineralization zones in the 
control samples (D–F). 
Staining for BSP2, which is a noncollagenous bone matrix protein produced by early 
committed osteogenic cells, was markedly increased in the periphery of osteogenic 
differentiated WJ biopsy specimens (Fig. 6A), with the intensity being maximal around the 
mineralization deposits (Fig. 6B). In control specimens BSP2 staining was negative (Fig. 6C,D). 
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Fig. 6. BSP2-positive staining in the periphery of WJ biopsy specimens after 21 days of 
in vitro differentiation with osteogenic factors (A). The BSP2 staining intensity 
(B, solid arrow) was maximal around the bluish hydroxyapatite deposits (B, dashed 
arrow). Control samples without osteogenic factors were negative for BSP2 (C, D). 
 
In vitro three-dimensional osteogenic differentiation of WJMSCs 
For clinical application, WJMSCs need to be loaded into constructs that are adaptable to 
defects of variable shape. WJMSCs were included into constructs of hydroxyapatite granules 
(Fig. 7A) and fibrin. After 3 weeks of osteodifferentiation in vitro, the cells formed a dense 
cell layer around the hydroxyapatite granules (Fig. 7B,C), with a high rate of cellular survival 
(Fig. 7D). 
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Fig. 7. Hydroxyapatite granules (A) were combined with WJMSCs and fibrin within osteogenic 
constructs (B). After 21 days of in vitro osteodifferentiation a dense cell layer formed around 
the hydroxyapatite granules (B, C), with high viability marked by green cytoplasmic 
fluorescence and a few dead cells marked by red nuclei fluorescence (D). (A, B; increments on 
the scale are millimeters) 
Immunohistochemistry for collagens I and V was performed to further analyze the fibrillar 
matrix, and for BSP2 and α-SMA to identify osteoprogenitor cells and myofibroblasts. The 
WJMSCs within the fibrin-hydroxyapatite constructs synthesized abundant collagens I and V, 
in both the differentiation (Fig. 8A,B) and control samples (Fig. 8E,F). However, 
osteodifferentiated constructs (Fig. 8C,D) —but not controls (Fig. 8G,H)—exhibited layers of 
strongly BSP2- and α-SMA-stained cells toward the osteogenic medium and hydroxyapatite 
granules. 
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In vivo testing of osteogenic potential of serum-free cultured WJMSCs 
The intrinsic bone-forming capacity of naïve human WJMSCs was investigated by implanting 
constructs of hydroxyapatite granules and fibrin with and without WJMSCs subcutaneously 
into immune-incompetent mice. After 8 weeks, the cell loaded constructs displayed a 
uniform tissue (Fig. 9A,B) of higher density than in acellular controls (Fig. 9E,F). The cell 
loaded constructs displayed a dense fibrillar extracellular matrix (Fig. 9C), and all of the 
granules were surrounded by a dense continuous cell layer (Fig. 9D). Control acellular 
constructs exhibited only loose connective tissue between the granules(Fig. 9G,H). 
 
Fig. 9. Constructs of hydroxyapatite granules and fibrin with (A–D) and without (E–H) human 
WJMSCs after 8 weeks of subcutaneous implantation in immunoincompetent mice. WJMSC-
containing constructs formed a dense uniform tissue (A, B) with fibrillar matrtix (C, D) and the 
hydroxyapatite granules were surrounded by continuous cell layers (D, arrow). In constructs 
Fig. 8. WJMSC constructs with fibrin and hydroxyapatite synthesized abundant collagens I and V 
after 21 days of differentiation in the presence (A, B) and absence (E, F) of osteogenic factors. 
(C, D) Under the influence of osteogenic factors, BSP2 and α-SMA-positive cells accumulated in 
lamellar cell layers (solid arrow) toward the medium-containing area outside the construct (~) 
and hydroxyapatite granules inside the constructs (*). (G, H) In the control condition, BSP2- and 
α-SMA-positive cells were randomly distributed in the matrix (dashed arrow). 
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without WJMSCs, the tissue was irregular and loose (E, F, G), no cell layer formed around the 
granules (H, arrow). (*, Lacunae of hydroxyapatite granules; HE, Hematoxylin and eosin). 
The staining for specific DNA human Alu sequences confirmed that the cells within the dense 
fibrillar matrix were derived from the human WJMSCs (Fig. 10A,B), whereas the staining was 
absent in acellular constructs (Fig. 10D-F). The human cells within the matrix displayed 
spherical large nuclei (Fig. 10C). 
 
Fig. 10. Cells of human origin were identified by staining for human-specific Alu sequences. 
Constructs of hydroxyapatite granules and fibrin with (A-C) and without (D-F) human 
WJMSCs after 8 weeks of subcutaneous implantation in immunoincompetent mice. (A, B) 
Human WJMSCs are embedded within the dense lamellar matrices, as highlighted by the 
purple nucleus staining. (C, arrow) The WJMSCs showed spherical large nuclei. Constructs 
devoid of human WJMSCs were negative for human Alu sequence staining (D-F). (*, Lacunae 
of hydroxyapatite granules). 
Furthermore, α-SMA staining revealed intense labeling of the cell layers adjacent to the 
hydroxyapatite granules (Fig. 11A,B). This finding was similar to that for the in vitro 
differentiated samples (Fig. 8D). In control acellular constructs, the granules were not 
surrounded by α-SMA-positive cells (Fig. 11C,D). The smooth muscle cells of the vessel walls 
(Fig. 11B,D, dashed arrows) allow the distinction of positive α-SMA staining from the 
background stain. 
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Fig. 11. Constructs of hydroxyapatite granules and fibrin with (A, B) and without (C, D) 
human WJMSCs after 8 weeks of subcutaneous implantation in immunoincompetent 
mice. (A) WJMSC-containing constructs formed a dense organized matrix around the 
hydroxyapatite granules. (B) The cells next to the granules stained strongly positive for 
α-SMA (B, solid arrow), as expected for osteoprogenitor cells. (C) In constructs devoid of 
human WJMSCs, the connective tissue was looser and (D) α-SMA-positive cells were 
absent around the granules (D, solid arrow). α-SMA staining of blood vessels acts as a 
positive control for α-SMA (B, D, dashed arrows). (*, Lacunae of hydroxyapatite 
granules). 
 
 
Discussion 
The stem cell type and donor site, its regenerative potential, and the intended therapeutic 
use must be closely aligned to increase the chance of successful clinical translation. In 
newborns, the umbilical cord is -in contrast to fat or bone marrow- an abundant MSC source 
without donor site morbidity. Since the cleft lip and palate is recognized at birth, the 
patient’s own WJMSCs could be preserved for bone regeneration. Stem cell induced bone 
regeneration for cleft patients would be interesting beyond its use as an autologous bone 
graft. More important, bone regeneration which complies with craniofacial growth could be 
targeted. Since this is currently not achieved, almost 50% of cleft lip and palate patient show 
at the end of growth a short upper jaw with need of surgical correction to improve jaw 
relation and facial profile [9]. The clinical translation of a stem cell based concept critically 
depends upon whether it functions under fully defined conditions [10]. We therefore 
focused on this aspect while developing a protocol of autologous bone formation from 
WJMSCs. 
WJMSCs are well protected in the umbilical cord and always survived for up to 48 h at RT in 
the present study. This time window eases the clinical handling of WJMSCs. The cord piece 
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can be quickly obtained even in the rush of a delivery, and can later be processed for 
cryopreservation or transferred into a designated laboratory. Even storage at –80°C for up to 
at least 1 year appears to be possible; it is therefore feasible to temporarily store WJMSCs in 
operating-room freezers, which are commonly available for autologous bone grafting. The 
isolation technique allowed the removal of 32×106 WJMSCs from a 10-cm cord piece at 
passage 1; this is sufficient for 10 constructs of 5-mm diameter, which allows the filling of 
cleft alveolar bone defects of any shape. 
The WJMSC CD marker signature observed in the present study matched well the commonly 
described MSC phenotypes of adipose tissue and bone marrow, with the exception of 
immunostaining for CD106, which was negative in WJMSCs, whereas in bone marrow MSCs 
it is commonly expressed (Table 3). CD106 corresponds to vascular cell adhesion molecule 1, 
which mediates the adhesion of white blood cells and is not a mesenchymal-specific stem 
cell marker. Accordingly, in adipose-tissue-derived MSCs, CD106 is reportedly variably 
positive [10,11] or even negative [12]. Although defined CD marker signatures are commonly 
described for distinct MSC phenotypes, individual marker cannot predict the clinical 
performance of bone formation. Thus, regardless of the question as to whether WJMSCs are 
true MSCs [13], their ability to form bone remains to be established. 
Osteodifferentiated WJMSCs exhibited characteristic mineralization in monolayers. The 
serum-free isolation, cryopreservation, and re-expansion did not inhibit its osteogenic 
differentiation capacity. In line with the histology, the expression of early and specific genes 
downstream to osteogenesis increased significantly under osteogenesis: the expression of 
RUNX2 increased and up-regulated the transcription of OSX and ALPL, and the expression of 
Hoxa10 increased, which is a functional element in osteoblast genes, including OCN, BSP2, 
and ALPL [14]. Accordingly, with respect to ongoing cell differentiation, the state of both of 
the cell signaling cascades, WNT and JAK-STAT, favored MSC migration [15] and osteogenic 
differentiation [16], respectively. 
Osteodifferentiated WJ biopsy specimens exhibited hydroxyapatite mineralization in the WJ 
matrix, which we attribute to osteodifferentiation of WJMSCs within their natural niche. 
Bone sialoprotein, is a major noncollagenous glycoprotein of the bone matrix that promotes 
the initiation of mineralization. Accordingly, it was found in maximal concentrations around 
the hydroxyapatite particles. To our knowledge this is the first report on the osteogenic 
differentiation of native WJ tissue. The structural similarity between the extracellular matrix 
of WJ and bone, both comprising collagen I with coassembled collagen V [17], might be an 
advantage for bone tissue engineering based on WJ or WJMSCs. However, more studies, in 
particular in vivo implantation of WJ tissue in an ectopic or orthotopic model, will have to be 
performed to challenge the clinical suitability of this approach. 
When isolated and reintroduced into compounds with fibrin and bone substitute material, 
WJMSCs continue to produce collagens I and V, just as in WJ, regardless of the presence of 
osteodifferentiation factors. However, cells producing BSP-2 accumulated toward the media 
and bone substitute compartments uniquely under the influence of osteogenic medium. This 
osteodifferentiation-medium-dependent distribution pattern of osteoprogenitor cells was 
confirmed by α-SMA immunostaining. Although α-SMA is mainly a marker of myofibroblasts, 
it is also expressed in cells that differentiate into osteoblasts [18,19] or are already engaged 
in bone formation [20]. Thus, we hypothesize, that the osteodifferentiation ability of 
WJMSCs within constructs withstand the serum-free cultivation method. 
85 
 
The in vivo bone-forming capacity of WJMSCs was tested in a standard in vivo model in 
which at the time of implantation, the compounds contained naïve WJMSCs without 
osteogenic predifferentiation; those compounds were implanted subcutaneously, thus 
excluding signaling from bone. Despite these two factors, the WJMSCs started to produce a 
dense lamellar matrix around the hydroxyapatite granules. The therein embedded WJMSCs 
displayed large spherical nuclei, resembling to osteoblastic lineage cells . Additionally, the 
WJMSCs next to the hydroxyapatite granules stained strongly positive for α-SMA, which 
potentially indicates a preserved osteodifferentiation capcity. The differentiation ability 
might be due to the biophysical stimulus of the hydroxyapatite and its porosity, which can 
direct stem cells toward the osteodifferentiation path, even in the absence of additional 
chemical stimuli. Although the serum-free cultured WJMSCs produced an unmineralized 
matrix similar to bone, the differentiation was not sufficient to produce woven or lamellar 
bone within an 8-week period. 
The data in the literature regarding the ability of WJMSCs to produce ectopic bone after 
12 weeks are inconsistent. While mature bone formation has been reported for 
predifferentiated WJMSCs on hydroxyapatite–polylactic-acid scaffolds [21], others have 
found a solely mineralized matrix, but no mature bone, when using predifferentiated 
polycaprolactone-tricalcium-phosphate-WJMSC constructs [2]. Nonetheless, 
predifferentiation of WJMSCs might critically enhance their ability to form bone in vivo. 
Predifferentiation has also been applied to tests of orthotopic bone formation by WJMSCs 
[22,23]. In vitro predifferentiation is commonly performed with bovine serum, which is 
difficult to replace with fully defined components. In the future, autoserum from the cord 
blood could be an option to satisfy autologous and fully defined conditions [24]. 
A striking finding of our work concerned the conversion of WJ tissue into mineralized tissue 
under osteogenetic differentiation. This raises new options for bone-regenerative 
techniques from the umbilical cord. The long survival time of WJMSCs after umbilical cord 
harvesting, combined with the 100% success rate of serum-free WJMSC expansion and 
storage, renders WJ an ideal donor tissue for autologous bone tissue engineering for cleft lip 
and palate. We present herein an in vivo protocol in which WJMSCs exhibit signs of 
osteogenic commitment and form a dense collagenous matrix under fully defined 
conditions, and which is compatible with clinical translation. However, more work is 
required to achieve mature bone from WJMSCs under fully defined conditions in vivo. The 
enhanced bone-forming capacity of WJMSCs might be possible with in vitro 
predifferentiation using autologous serum, longer in vivo differentiation times, the use of a 
modified bone substitute material, the addition of bone-signaling molecules, or orthotopic 
implantation. 
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Table 1. Antibodies for fluorescence activated cell sorting 
Marker Fluorochrome Provider Reference 
CD10 PE BD Biosciences 555375 
CD13 APC BD Biosciences 557454 
CD15 V450 BD Biosciences 642917 
CD31 FITC BD Biosciences 555445 
CD34 APC BD Biosciences 555824 
CD44 APC-H7 BD Biosciences 560532 
CD45 V500 BD Biosciences 560777 
CD73 PE-Cy7 BD Biosciences 561258 
CD90 FITC BD Biosciences 555595 
CD105 PE BD Biosciences 560839 
CD133 PE Miltenyi Biotech 130-090-853 
CD106 FITC BD Biosciences 551146 
CD166 PE BD Biosciences 559263 
HLA-ABC V450 BD Biosciences 561346 
HLA-DR V500 BD Biosciences 561224 
FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin; BD Biosciences, 
San Jose, CA, USA; Miltenyi Biotech GmbH, Bergisch Gladbach, Germany. 
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Table 2. Primers for quantitative real time polymerase chain reaction of gene expression 
Gene Reference BP Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
ALPL NM_000478.4 132 TATAAGGCGGCGGGGGTGGT TGTTCCAATCCTGCGCAGAGCAC 
BGLAP (OCN) NM_199173.4 159 CCTATTGGCCCTGGCCGCAC ACTGGGGCTCCCAGCCATTGA 
CTNNB1 NM_001904.3 260 TGGCCCAGAATGCAGTTCGCC CATGCGGACCCCCTCCACAAA 
DKK1 NM_012242.2 139 TTGACAACTACCAGCCGTACCCGT CGCATGCAGCGTTTTCGGCG 
HOX-A10 NM_018951.3 167 GAGCGAGCCCTCGATTCGCC GAATTGCCCAGGGAATCCTTCTCCG 
IBSP (BSP2) NM_004967.3 76 CCAGAGGAAGCAATCACCAAA TTGAGAAAGCACAGGCCATTC 
OSX NM_001173467.1 77 CACTCTCCCTGCCAGACCTCCAG GCAGATGGAGAGAGCTGGGGGAAC 
RUNX2 NM_001024630.3 128 ACAGAACCACAAGTGCGGTGCA TGCTTGCAGCCTTAAATGACTCTGT 
STAT3 NM_139276.2 129 CGGCTTGGCGCTGTCTCTCC CAGGGGTCCCAACTGTTTCTCCG 
GAPDH NM_002046.3 170 GGCTGGGGCTCATTTGCAGGG TGACCTTGGCCAGGGGTGCT 
r18S NM_022551.2 345 ACCAACATCGATGGGCGGCG TCGGACACGAAGGCCCCAGA 
PTK9 BT019691.1 190 CCAGACCGGCATCCAAGCAAGT TGGTTGTTTGTCCTCCAACAGGGG 
BP, Product size in base pairs. 
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Table 3. MSC marker expression in serum free cultured WJMSC compared to known expressions in BMMSC, ATMSC andWJMSC 
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BMMSC ‡                 
ATMSC †                  
WJMSC *             NA       NA 
MSC, mesenchymal stromal cell; WJMSC, Wharton’s-jelly derived MSC; BMMSC, bone marrow derived MSC; ATMSC, adipose tissue derived MSC; 
NA, not applicable; ●, negative expression ; ●, positive expression; * Results compiled from [3,13,21,22,23,25,26,27]; † Results compiled from 
[10,11,12,28]; ‡ Results compiled from: [10,11,13,28]. 
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7. Discussion and Outlook 
The following chapter outlines, how the studies relate to current techniques of biomedical 
engineering and how they can contribute to the development of new surgical concepts. 
Based on this analysis, next promising research projects will be defined and subsequently 
targeted. 
 
Computer assisted design and manufacturing for partial facial reconstruction 
The morphable face model in the first study lead to realistic facial shape reconstruction of 
the missing nose-lip region, for which no contralateral side is available to act as a shape 
reference (Fig. 1).1 The direct manufacture of the nose prosthesis from skin-colored 
polyamide by laser sintering fulfilled the requirements for temporary use. In a next step 
adjustable coloring and margin adjustments with a self-curing resin must be developed to 
reach the standard of permanent use. 
 
Fig. 1. Patient after nose and eye resection due to invasive skin cancer (A). The morphable face 
model leads to a natural shape reconstruction of the missing facial is part (B, white facial part). The 
modeled facial part contains complete shape information and can thus directly transferred into a 
scaffold for prosthetic or tissue engineering use (C). 
The use of the morphable face model is not limited to prosthesis manufacturing. The shape 
designed could also be used for computer assisted manufacturing of patient specific 
scaffolds for tissue regeneration. Computer assisted manufacturing has been applied to 
bone substitute scaffold made from polycaprolactone, polyglycolic acid, and calcium 
phosphate cements.2,3 Aside the osteogenic scaffolds, collagen could be molded into a cast 
of patient specific shape, to generate patient specific constructs from chondocytes.4 
To engineer large tissue engineered constructs creates two difficulties. First, to seed the cells 
with a regular density throughout the constructs. Second, to ensure the blood supply for 
nutrition and oxygen delivery to the cells in the center of the scaffold. In vitro this problem 
can be solved by using a bioreactor, in which the scaffold is perfused for cell seeding and 
nutrition.5 However, at the time of implantation of the large scaffolds, there is no vessel 
connected to the scaffold that can take over the perfusion function of the bioreactor. 
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Microsurgery to connect tissue or engineered constructs to the blood flow 
Vascular microsurgery offers techniques to promote the vascularisation of implanted tissue 
engineered constructs. Mandibular reconstruction has been performed by implanting 
subtotal mandibular constructs made from hydroxyapatite, cancellous bone graft and BMP-
7, temporarily into a cuff of latissmus dorsi muscle.6 The muscle which contained the 
construct was transplanted in a second stage as a microvascular latissimus dorsi graft into 
the defect area. Similarly, a tissue engineered nasal framework could be implanted 
temporarily into a distant body site, to ensure vascularisation, maturation and soft tissue 
covering of the construct. Due to its bulkiness a muscle cuff would not allow natural shape 
contours of the nasal framework, but a vascularized periostal graft could be suitable. The 
periosteum in the supracondylar region of the distal femur could be an ideal donor site 
(Fig. 2). The periost vascularization in this region is constantly delivered by ramifications of 
the descending genicular artery and its accompanying veins.7 
 
Fig. 2. Microvascular periostal or periostal-bone graft. Skin incision outlined 
from the medial femoral condyle ascending the thigh (A). The descending 
genicular artery which supplies the periost over the medial condyle is 
identified (B) and the periost, with or without underlying bone, can be 
harvested (C). 
Surgical techniques and perioperative medical management of microsurgical reconstruction 
vary largely among surgical teams. In the second study we therefore assessed the current 
practice in microsurgical head and neck reconstruction in maxillofacial units of Germany, 
Switzerland and Austria.8 It showed, that microsurgical techniques have become a routine 
technique for maxillofacial reconstructive surgery in the majority of the departments. The 
key to success of microsurgical intervention showed to be strongly related to the surgical 
technique and not to postoperative medication regimen. Therefore microsurgical techniques 
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can be considered as a valid surgical option to be combined within tissue engineering of 
large constructs in order to promote the blood and nutrition supply to the constructs. 
The implantation of tissue engineered construct at a distant implant site and subsequent 
transplantation to the defect site has two drawbacks. It is a two-stage procedure and the 
vascularization is extrinsic, growing from the exterior surface to the center of the constructs. 
Therefore an alternative technique has been described, in which at the time of scaffold 
implantation a microvascular arterio-venous loop is positioned into the center of the 
constructs.9 By this means an axial vascularization from inside the construct (intrinsic) can be 
achieved (Fig. 3). 
 
Fig. 3. Principle for axial vascularization of a tissue engineering construct. A 
vessel is inserted into the tissue engineering construct (cylinder) that leads 
to vascular outspread inside the construct (grey vessel portion). 
The anatomical part of the third study reveals suitable vascular connection sites in the face 
to support a tissue-engineered construct in the nose region.10 A tissue engineered construct, 
from the type of axial vascularization or vascularized periost, can be microsurgically 
anastomosed to the facial artery and vein, which has a prominent diameter at the height of 
the labial commissure (Fig. 4). The surgical access to the facial artery and vein, as well as the 
microsurical anastomosis, can be performed from intraorally, with no need for a visible 
surgical incision in the face .11 
 
Fig. 4. Possible arterial and venous anastomosis sites (circles) 
for vascularized nasal tissue grafts. The facial artery (red) and 
vein (blue) can be accessed from intraorally. 
To date, no small caliber vascular substitutes exists that can be used as implants in clinical 
routine. However, the use of bacterial synthetized cellulose allowed to produce 10 mm long 
arterial substitutes of 3 mm internal diameter that show a 88% patency rate after 3 month 
as carotid interposition graft in pigs (Fig. 5).12 The bacterial cellulose synthesis is made from 
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glycan extrusion from Gluconacetobacter xylinus bacteria that aggregates into microfibrils. 
Currently, the endothelialisation and patency rate of 10 and 15 cm long small caliber grafts is 
studied. 
 
Fig. 5. Bacterial synthetized vascular graft with a minimal inner diameter 
of 3mm (d). At the end of production the graft is stored sterile in 0.9% 
NaCl. Specimen donated by Prof. Dieter Schumann, Polymet Jena, 
Germany. 
Although small caliber vessels are engineered with the main clinical application for coronar 
vascular heart surgery, their potential for vascularization techniques of large tissue 
engineering constructs remain to be explored. 
 
Normal vascular blood flow and microcirculation after cleft lip surgery 
The importance of vascular development and blood flow applies for tissue engineering 
constructs as well as for the entire organism. The blood flow ensures the supply of oxygen, 
nutrients and defense cells to the tissue. As such it is a driving force of development and 
growth. 
Despite its biological importance, the functional vascular anatomy remains unexplored in the 
cleft lip, which is one of the most frequent inborn malformations, that occurs in about every 
seven hundredth newborn. The cleft lip divides lip and nostril and interrupts the normal 
vascular anatomy of the lip-nose region. This prompted us to investigate the 
microcirculation and the intraoperative vascular anatomy in cleft lip and palate surgery, 
which forms the clinical part of the third study.10 In sum, the microcirculation 
measurements showed, that before and after lip repair the microcirculation in the lip-nose 
regions is equal to normal control and no evidence was found that would urge an 
microvascular reconstruction of the separated lip artery. In bilateral cleft lips, the prolabium, 
which is the island-like central lip part, showed a significant higher microcirculation than in 
normal, indicating a high hemodynamic and nutritional need in this region. If only a small 
soft tissue bridge is present on both sides, the preferential connection to the lip artery is 
established nonetheless (Fig. 6, A,B). Just, if the prolabium is completely separated from the 
lip, strong arterial connection forms to the dorsal nasal artery (Fig. 6 C,D). 
99 
 
 
Fig. 6. Intraoperative vascular anatomy in bilateral cleft lip. If the cleft is 
incomplete (A) the central lip part still connects to the lateral lip part (B). 
In complete bilateral clefts (C) the prolabium must connect to the dorsal 
nasal artery (D). 
The high hemodynamic and nutritional need in the central lip region might also reflect a 
functional hemodynamic contribution of the lip to the underlying bone. There is an intimate 
morphological connection between the microvascular network of the lip (Fig. 7A) and the 
anterior bony part of the maxilla (Fig. 7B), as visualized by anatomical corrosion casts. 
 
Fig. 7. The vascular network of the lip (A, circle) is intimately 
connected with that of the anterior maxillary bone (B, circle). 
Anatomical preparation by G.-R. Klaws, Kiel, Germany. 
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Due to the vascular morpho-functional relation between lip and underlying bone, it seems 
therefore advisable, that the cleft lip surgery technique should interfere as less as possible 
with this contiguous vascular territory. We therefore advance the lip from the cleft side to 
the midline without detachment or releasing incision on the alveolus. 
Arteriogenesis, which is the recruitment of arterioles and enlargement of collateral vessels13, 
is assumed to be the main mechanism for arterial flow restoration after cleft lip surgery. The 
conditions for this are favorable in the lip, due to the rich arterial network (Fig. 7A,B) and 
because arteriogenesis is known to be accelerated, the more dense the preexisting collateral 
network is.14 
 
The need to recapitulate normal development in cleft lip and palate defects 
Despite delicate surgical techniques, patients with a combined cleft of the lip and palate 
(Fig. 8), show at the end of growth frequently a short upper jaw. In literature frequencies of 
up to 48% of these patients are reported to undergo surgical maxillary advancement at end 
of growth.15 In an attempt to reduce the maxillary growth deficiency, many different surgical 
techniques have been proposed and lead to a high variability of treatment plans to close a 
cleft lip and palate defect. Grossly, treatment plans vary on; 1) The number of surgeries used 
to close the lip, alveolar part of the maxilla, hard and soft palate (Fig. 9); 2) The sequence in 
which lip, hard- and soft palate is closed; 3) The age of the patient at the time of the 
surgeries. 
  
Fig. 8. Maxillary growth deficiency. (A) Patient at 5 
month of age before one-stage cleft lip, alveolus, hard- 
and soft palate repair. (B) Patient at 17 years, without 
having undergone jaw corrective surgery, exhibit 
shortness of the upper jaw. 
 Fig. 9. Complete cleft lip and 
palate. The anatomical portions 
of the cleft comprise: lip (L); 
alveolar part of the maxilla where 
teeth will erupt (A); osseus hard 
palate (H); and muscular soft 
palate (S). 
Due to variations in the sequence and number of operations to close a cleft lip and the 
patients age at the time of surgery, the treatment schedule vary widely in european 
countries .16 Consequently, growth findings from a specific treatment plan have only limited 
validation for a diverging concepts. We assessed therefore the longterm growth results of 
the applied one-stage surgical concept of our clinic in the forth study.17The surgical closure 
of the cleft lip, alveolus and palate in one surgical procedure at the early age of 6 month 
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showed comparable growth results as compared to staged procedures at a later stage. 
However, the results indicated, that the early interposition of a rib bone graft into the 
alveolar cleft might inhibit the growth. The osseus fusion might block the growth movement 
of the anterior maxilla. Early alveolar bone grafting has also shown negative growth effects 
in combination with multi-staged closure of cleft lip and palate defects. It has therefore 
become common sense, to postpone the osseous bridging of alveolar cleft to the late 
preteen age, when most of the craniofacial growth has taken place and when the permanent 
teeth need to be aligned in the cleft area.17 
 
Fig. 10 Alveolar bone grafting at preteen age. Although ghe gum of the alveolar maxillary parts 
are in contact a broad gap in the dental arch remains (A, *). There width of the alveolar part of 
the maxilla is seen in the radiography (B, *). Cancellous graft from the patients pelvic bone is 
used to fill the alveolar cleft and to form a bony bridge between both maxillary parts (C, *). 
Despite a large variations of treatment protocols, there are two clinical shortcomings 
common to all treatment protocols: the need to postpone alveolar bone graft to late 
preteen age and the tendency of maxillary growth deficiency. Both implies major clinical 
drawbacks for the patient. First, leaving the alveolar cleft open to preteen age is associated 
with frequent adverse effects as: tongue interposition with speech problems, insufficient 
teeth alignment with biting problems, incomplete separation of oral and nasal cavity leading 
to food and speech emission through the nose. Second, the retruded maxilla cannot be 
surgically corrected until the growth has ceased and thus leaving the patient with a 
functional and psychosocial burden all over the teenage years. Given the countless surgical 
variations in use and the persistently high percentage of growth deficiencies, it is doubtful 
that surgery alone can ever provide the solution. 
Tissue engineering might allow for new treatment plans, being less traumatic and leading to 
real tissue regeneration as in normal development. The most obvious way to use an 
osteogenic cell construct would be as an alternative to the alveolar bone graft. However, this 
alone has limited advantage for the patient, since the cancellous bone graft is very efficient 
with minimal donor site morbidity. Therefore a more promising way to use osteogenic cells 
would be the realization of an midpalatal growth zone, by recapitulating the suttural bone 
formation - similar to what has been achieved for endochondral bone formation.19 
 
Clinical translation of cord stem cells to treat inborn craniofacial defects 
Stem cells, having the ability to develop towards mature cells of different tissues, are the 
basic material to engineer tissues. The stem cells that are able to differentiate into mature 
cells as from fat, cartilage and bone are called mesenchymal stem cells (MSCs). MSCs are 
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found in numerous tissues, and among others in the umbilical cord. Since the cleft 
malformation is frequently known before birth, due to prenatal ultrasound, the umbilical 
cord could serve as an autologous MSCs donor site without any harvesting morbidity for the 
cleft patient (Fig. 11). 
 
Fig. 11. Prenatal ultrasound at 37th week of pregnancy. Sagittal 
section (A) and three-dimensional surface image of the face 
showing a right sided complete cleft lip and palate (B). 
This could offer the opportunity to use the patient’s own umbilical cord to engineer bone 
tissue at the time, when it is needed for cleft treatment. A requirement for translation of a 
given tissue engineering protocol into clinical application is to dispense from potential 
infectious or immunogenic animal-derived products. In the fifths study we therefore studied 
umbilical cord MSCs for bone tissue engineering under conditions that would allow for 
clinical translation (Fig. 12).  
 
Fig. 12. From the umbilical cord to osteogenic constructs. From the Wharton’s Jelly part of the 
umbilical cord (A) mesenchymal stromal cells (MSCs) are isolated (B). MSCs are combined with fibrin 
sealant (C) and synthetitc hydroxyapatite bone substitutes (D) to form osteogenic constructs (E) 
(Increments on the scale are millimeters). 
Our protocol allowed for successful isolation and expansion of MSCs from the Wharton’s 
jelly tissue of the umbilical cord. After 3 weeks of subcutaneous implantation into 
immunoincompetent mice the cells showed early stages of osteogenic differentiation but 
mature bone formation was absent. Mature bone formation could not be readily expected, 
since the implanted cells were naïve without in vitro predifferentiation towards osteoblasts 
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and the cells were implanted under the skin, where osteogenic stimulation is lacking. In a 
next step, the protocol will include the use of predifferentiated WJMSCs and implantation 
into a bone defect, which both should favor the bone forming capacity. 
A bone tissue engineering approach could also be an interesting treatment option for 
malformations or defects of the cranial vault. In Craniosynostosis the bone plates of the 
cranial vault show a bony fusion and they lack the natural interposed growth zone 
(Fig. 13A,B). After birth the rapidly growing brain suffers therefore from being rigidly 
encased and recall surgical release of the cranial bone plates. In the course of growth after 
the surgical release broad gaps or osseus defect might form between the bone plates, 
demanding cranial bone substitution (Fig. 13C,D) 
 
Fig. 13. Inborn fusion of the frontal (A, arrow) and parietal 
(B, arrow) bone plates with need for surgical release (A,B at 7 month 
of age). After release of the bony fusion extensive bony gaps in the 
cranial vault can persist (C,D at 8 years of age). 
Large non healing cranial vault defects in the growing patient are difficult to treat. Synthetic 
bone substitutes lack osseus integration and become unfitting in the course of growth and 
have a risk of infection – while split bone grafts from healthy cranial vault parts necessitates 
a good bone thickness over a large cranial vault area, which is often lacking. A tissue 
engineering approach, that uses the patient’s own mesenchymal stem cells for cranial vault 
regeneration could be advantageous for growing patients. 
We have previously shown, as a proof of principle, that cranial defects that do not 
spontanaeusoly heal can be regenerated by use of guided bone regeneration - even in 
absence of osteogenic stem cells (Fig. 14).20 For large non-healing cranial defects, the 
efficiency of this technique by adding osteogenic stem cells need to be explored. In the first 
two years of life the cerebral membrane has a natural ability to regenerate the cranial vault 
in humans. We reproduced this effect in the cranial defect model in rabbits.21 Enhancing the 
bone forming capacity of the cerebral membrane, by use of stem cells, could be an 
alternative approach to treat non-healing cranial defects. 
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Fig. 14. Critical size cranial defect model. (A) Bilateral cranial defects of 8 mm diameter are made 
in rabbits since they do not spontaneously heal. (B) The principle of guided bone regeneration is 
applied using a polylactide foil on the inner (fi) and outer (fo) defect surface and a spacer in 
between (s). (C) After 8 weeks the bone edges (b) have grown towards the center of the defect 
and new bone forms within the dura (d, arrows). Mueller and Leiggener, AO Research Institute, 
Davos, Switzerland 
 
Conclusion 
We herein present biomedical engineering strategies to overcome particular surgical 
challenges to reconstruct lip-nose defects - both from traumatic and inborn origin. The used 
strategies comprised databank based facial planning, computer assisted manufacturing, 
microsurgery, microcirculation and stem cell based tissue engineering. Each strategy 
exhibited promising solutions to the addressed surgical challenges to reconstruct tissue 
shape, function, cell content, and nutrition. It seems that even greater benefit for surgical 
care can arise from complementary use of these techniques. It is therefore beneficial for 
surgeons to be familiar with a wide range of biomedical engineering strategies and to 
participate in the development of such strategies. This allows to closely align the biomedical 
methods to the intended surgical strategy. 
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